

STIC-Biotech/ChemLib

162242

From: Bowman, Amy
Sent: Thursday, August 11, 2005 11:46 AM
To: STIC-Biotech/ChemLib
Cc: Bowman, Amy
Subject: sequence search-10/665,951

Hello,
I need SEQ ID NO: 2185 searched in application 10/665,951, length limited to 30 nucleotides.
Thank you,
Amy Bowman
AU 1635
REM 2C31
mail REM 2C18
571-272-0755

EDWARD HART

10/11/05
11:46 AM
STIC-Biotech/ChemLib

STAFF USE ONLY

Searcher: _____
Searcher Phone: 2- _____
Date Searcher Picked up: 8/17/05
Date Completed: 8/19/05
Searcher Prep/Rev. Time: _____
Online Time: _____

Type of Search

NA#: 1 AA#: _____
Interference: _____ SPDI: _____
S/L: _____ Oligomer: _____
Encode/Transl: _____
Structure#: _____ Text: _____
Inventor: _____ Litigation: _____

Vendors and cost where applicable

STN: _____
DIALOG: _____
QUESTEL/ORBIT: _____
LEXIS/NEXIS: _____
SEQUENCE SYSTEM: OSP
WWW/Internet: _____
Other(Specify): _____

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 22:19:12 ; Search time 1735 Seconds
(without alignments)
159.172 Million cell updates/sec

Title: US-10-665-951-2185

Perfect score: 21

Sequence: 1 cugaguuaaaagcaccm 21

Scoring table: IDENTITY_NUC

Gapop 10.0, Gapext 1.0

Searched: 23768202 seqs, 6575307184 residues

Total number of hits satisfying chosen parameters: 32118462

Minimum DB seq length: 0

Maximum DB seq length: 30

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Pending Patents NA New:

1: /cgn2_6/ptodata/1/pna/PCT_NEW_COMB.seq:
2: /cgn2_6/ptodata/1/pna/PCT_NEW_COMB.seq:
3: /cgn2_6/ptodata/1/pna/US06_NEW_COMB.seq:
4: /cgn2_6/ptodata/1/pna/US07_NEW_COMB.seq:
5: /cgn2_6/ptodata/1/pna/US08_NEW_COMB.seq:
6: /cgn2_6/ptodata/1/pna/US09_NEW_COMB.seq:
7: /cgn2_6/ptodata/1/pna/US09_NEW_COMB.seq:
8: /cgn2_6/ptodata/1/pna/US09_NEW_COMB.seq:
9: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
10: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
11: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
12: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
13: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
14: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
15: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
16: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
17: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
18: /cgn2_6/ptodata/1/pna/US10_NEW_COMB.seq:
19: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq:
20: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq:
21: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq:
22: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq:
23: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq:
24: /cgn2_6/ptodata/1/pna/US11_NEW_COMB.seq:
25: /cgn2_6/ptodata/1/pna/US60_NEW_COMB.seq:

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	19	90.5	19	13	US-10-944-611-2809
C 2	19	90.5	19	13	US-10-944-611-2967
C 3	19	90.5	19	13	US-10-944-611-2977
C 4	19	90.5	19	13	US-10-944-611-3139
C 5	19	90.5	19	13	US-10-944-611-3141
C 6	19	90.5	19	13	US-10-944-611-3143
C 7	19	90.5	19	13	US-10-944-611-3144
C 8	19	90.5	19	14	US-10-962-898-2809
C 1	19	90.5	19	13	Sequence 2809, Ap
C 2	19	90.5	19	13	Sequence 2967, Ap
C 3	19	90.5	19	13	Sequence 2977, Ap
C 4	19	90.5	19	13	Sequence 3139, Ap
C 5	19	90.5	19	13	Sequence 3141, Ap
C 6	19	90.5	19	13	Sequence 3143, Ap
C 7	19	90.5	19	13	Sequence 3144, Ap
C 8	19	90.5	19	14	Sequence 2809, Ap

9	19	90.5	19	14	US-10-962-898-2967	Sequence 2967, Ap
C 10	19	90.5	19	14	US-10-962-898-2977	Sequence 2977, Ap
C 11	19	90.5	19	14	US-10-962-898-3139	Sequence 3139, Ap
C 12	19	90.5	19	14	US-10-962-898-3141	Sequence 3141, Ap
C 13	19	90.5	19	14	US-10-962-898-3143	Sequence 3143, Ap
C 14	19	90.5	19	14	US-10-962-898-3144	Sequence 3144, Ap
C 15	19	90.5	19	14	US-10-944-611-2966	Sequence 2966, Ap
C 16	19	90.5	20	13	US-10-944-611-2976	Sequence 2976, Ap
C 17	19	90.5	20	14	US-10-962-898-2966	Sequence 2966, Ap
C 18	19	90.5	20	14	US-10-962-898-2966	Sequence 2966, Ap
C 19	19	90.5	21	9	US-10-727-780A-23	Sequence 23, Appl
C 20	19	90.5	21	9	US-10-727-780A-24	Sequence 24, Appl
C 21	19	90.5	21	13	US-10-944-611-2742	Sequence 2742, Ap
C 22	19	90.5	21	13	US-10-944-611-2745	Sequence 2745, Ap
C 23	19	90.5	21	13	US-10-944-611-2763	Sequence 2763, Ap
C 24	19	90.5	21	13	US-10-944-611-2765	Sequence 2765, Ap
C 25	19	90.5	21	13	US-10-944-611-2767	Sequence 2767, Ap
C 26	19	90.5	21	13	US-10-944-611-2769	Sequence 2769, Ap
C 27	19	90.5	21	13	US-10-944-611-2777	Sequence 2777, Ap
C 28	19	90.5	21	13	US-10-944-611-2778	Sequence 2778, Ap
C 29	19	90.5	21	13	US-10-944-611-2843	Sequence 2843, Ap
C 30	19	90.5	21	13	US-10-944-611-2844	Sequence 2844, Ap
C 31	19	90.5	21	13	US-10-944-611-2845	Sequence 2845, Ap
C 32	19	90.5	21	13	US-10-944-611-2846	Sequence 2846, Ap
C 33	19	90.5	21	13	US-10-944-611-2864	Sequence 2864, Ap
C 34	19	90.5	21	13	US-10-944-611-2865	Sequence 2865, Ap
C 35	19	90.5	21	13	US-10-944-611-2868	Sequence 2868, Ap
C 36	19	90.5	21	13	US-10-944-611-2872	Sequence 2872, Ap
C 37	19	90.5	21	13	US-10-944-611-2876	Sequence 2876, Ap
C 38	19	90.5	21	13	US-10-944-611-2880	Sequence 2880, Ap
C 39	19	90.5	21	13	US-10-944-611-2925	Sequence 2925, Ap
C 40	19	90.5	21	13	US-10-944-611-2928	Sequence 2928, Ap
C 41	19	90.5	21	13	US-10-944-611-2931	Sequence 2931, Ap
C 42	19	90.5	21	13	US-10-944-611-2934	Sequence 2934, Ap
C 43	19	90.5	21	13	US-10-944-611-2937	Sequence 2937, Ap
C 44	19	90.5	21	13	US-10-944-611-2940	Sequence 2940, Ap
C 45	19	90.5	21	13	US-10-944-611-2953	Sequence 2953, Ap

ALIGNMENTS

RESULT 1

US-10-944-611-2809/c
; Sequence 2809, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944.611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796

Db 19 CTGAGTTTTAAAGGCACCC 1

RESULT 4

US-10-944-611-3139
; Sequence 3139, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3139
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region

US-10-944-611-3139
; Sequence 3141, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBHB02-742-S)

RESULT 5

US-10-944-611-3141/c
; Sequence 3141, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBHB02-742-S)

; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3141
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region

US-10-944-611-3141

Query Match 90.5%; Score 19; DB 13; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
|:||||:|||||||
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 6

US-10-944-611-3143
; Sequence 3143, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767

```

; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3143
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; US-10-944-611-3143

Query Match          90.5%; Score 19; DB 13; Length 19;
Best Local Similarity 100.0%; Pred. No. 8.4;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAGGCACCC 19
|:|||||:|||||
Db 1 CUGAGUUUAAAGGCACCC 19
|:|||||:|||||

RESULT 7
US-10-944-611-3144/c
; Sequence 3144, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT FILING DATE: 2004-09-16
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16

```

```

; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3144
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (1)..(3)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (12)..(14)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-O-methyl
; US-10-944-611-3144

Query Match          90.5%; Score 19; DB 13; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAGGCACCC 19
|:|||||:|||||
Db 19 CTGAGTTTAAAGGCACCC 1
|:|||||:|||||

RESULT 8
US-10-962-898-2809/c
; Sequence 2809, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT FILING DATE: 2004-10-12
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11

```

; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2809
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc.feature
; LOCATION: (20)..(20)
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: X stands for nitroindole universal base
US-10-962-898-2809

Query Match 90.5%; Score 19; DB 14; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
|:||||:|||||
Db 19 CTGAGTTTAAAAGGCACCC 1

RESULT 9
US-10-962-898-2967
; Sequence 2967, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBH02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2809
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-962-898-2967

Query Match 90.5%; Score 19; DB 14; Length 19;

; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2967
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc.feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
US-10-962-898-2967

Query Match 90.5%; Score 19; DB 14; Length 19;
Best Local Similarity 100.0%; Pred. No. 8.4;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
|:||||:|||||
Db 1 CUGAGUUUAAAAGGCACCC 19

RESULT 10
US-10-962-898-2977/c
; Sequence 2977, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBH02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2977
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
US-10-962-898-2977

Query Match 90.5%; Score 19; DB 14; Length 19;

```
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 11
US-10-962-898-3139
; Sequence 3139, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3139
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
US-10-962-898-3141

Query Match 90.5%; Score 19; DB 14; Length 19;
Best Local Similarity 100.0%; Pred. No. 8.4;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 12
US-10-962-898-3141/c
; Sequence 3141, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
```

```
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3141
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
US-10-962-898-3141

Query Match 90.5%; Score 19; DB 14; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 13
US-10-962-898-3143
; Sequence 3143, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
```

; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3143
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
US-10-962-898-3143

Query Match 90.5%; Score 19; DB 14; Length 19;
Best Local Similarity 100.0%; Pred. No. 8.4;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
|||||:|||||
Db 1 CUGAGUUUAAAAGGCACCC 19

RESULT 14
US-10-962-898-3144/c
; Sequence 3144, Application US/10962898
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Richards, Ivan
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/236 (MBHB02-742-U)
; CURRENT APPLICATION NUMBER: US/10/962,898
; CURRENT FILING DATE: 2004-10-12
; PRIOR APPLICATION NUMBER: US 10/944,644
; PRIOR FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348

; PRIOR FILING DATE: 2002-07-29
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 3144
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(3)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (5)..(5)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (12)..(14)
; OTHER INFORMATION: 2'-O-methyl
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (18)..(19)
; OTHER INFORMATION: 2'-O-methyl
US-10-962-898-3144

Query Match 90.5%; Score 19; DB 14; Length 19;
Best Local Similarity 78.9%; Pred. No. 8.4;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
|:|||||:|||||
Db 19 CTGAGTTTAAAAGGCACCC 1

RESULT 15
US-10-944-611-2966
; Sequence 2966, Application US/10944611
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: Jadhav, Vasant
; APPLICANT: Kossen, Karl
; APPLICANT: Zinnen, Shawn
; APPLICANT: Vaish, Narendra
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition Of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor And Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/235 (MBHB02-742-S)
; CURRENT APPLICATION NUMBER: US/10/944,611
; CURRENT FILING DATE: 2004-09-16
; PRIOR APPLICATION NUMBER: US 10/844,076
; PRIOR FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23

```

; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: US 10/664,767
; PRIOR FILING DATE: 2003-09-16
; PRIOR APPLICATION NUMBER: PCT/US03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: PCT/US04/16390
; PRIOR FILING DATE: 2004-05-24
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 4252
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2966
; LENGTH: 20
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc.feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: n stands for thymidine
US-10-944-611-2966

Query Match      90.5%; Score 19; DB 13; Length 20;
Best Local Similarity 100.0%; Pred. No. 8.4;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 CUGAGUUUUAAAAGGCACCC 19
        |||||
Db      1 CUGAGUUUUAAAAGGCACCC 19

Search completed: August 19, 2005, 00:02:13
Job time : 1736 secs

```

Pending Nucleic Acid and Pending Amino Acid database searches generate two sets of results each. The Pending databases have been split into two parts to reduce the amount of time required for their daily updates. This results in more machine time being available for processing searches.

Searches run against the Nucleic Acid Pending database produce two sets of results, with the extensions .rnpm and .rnpn

Searches run against the Amino Acid Pending database produce two sets of results, with the extensions .rapm and .rapn

Because they contain data that is confidential, the results of Pending database searches should not be left in the case .

This Page Blank (uspto'

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 22:15:08 ; Search time 3829 Seconds
(without alignments)
223.892 Million cell updates/sec

Title: US-10-665-951-2185
Perfect score: 21
Sequence: 1 cugaguuaaaaggaccacm 21

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 45554873 seqs, 20411521753 residues

Total number of hits satisfying chosen parameters: 35943252

Minimum DB seq length: 0
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Pending Patents NA Main.*

1: /cgn2_6/ptodata/1/pna/PCRTUS1_COMB.seq.*
2: /cgn2_6/ptodata/1/pna/PCRTUS2_COMB.seq.*
3: /cgn2_6/ptodata/1/pna/PCRTUS_COMB.seq.*
4: /cgn2_6/ptodata/1/pna/US06_COMB.seq.*
5: /cgn2_6/ptodata/1/pna/US07_COMB.seq.*
6: /cgn2_6/ptodata/1/pna/US080_COMB.seq.*
7: /cgn2_6/ptodata/1/pna/US081_COMB.seq.*
8: /cgn2_6/ptodata/1/pna/US082_COMB.seq.*
9: /cgn2_6/ptodata/1/pna/US083_COMB.seq.*
10: /cgn2_6/ptodata/1/pna/US084_COMB.seq.*
11: /cgn2_6/ptodata/1/pna/US085_COMB.seq.*
12: /cgn2_6/ptodata/1/pna/US086_COMB.seq.*
13: /cgn2_6/ptodata/1/pna/US087_COMB.seq.*
14: /cgn2_6/ptodata/1/pna/US088_COMB.seq.*
15: /cgn2_6/ptodata/1/pna/US089_COMB.seq.*
16: /cgn2_6/ptodata/1/pna/US090_COMB.seq.*
17: /cgn2_6/ptodata/1/pna/US091_COMB.seq.*
18: /cgn2_6/ptodata/1/pna/US092A_COMB.seq.*
19: /cgn2_6/ptodata/1/pna/US092B_COMB.seq.*
20: /cgn2_6/ptodata/1/pna/US093A_COMB.seq.*
21: /cgn2_6/ptodata/1/pna/US093B_COMB.seq.*
22: /cgn2_6/ptodata/1/pna/US094_COMB.seq.*
23: /cgn2_6/ptodata/1/pna/US095A_COMB.seq.*
24: /cgn2_6/ptodata/1/pna/US095B_COMB.seq.*
25: /cgn2_6/ptodata/1/pna/US095C_COMB.seq.*
26: /cgn2_6/ptodata/1/pna/US095D_COMB.seq.*
27: /cgn2_6/ptodata/1/pna/US096A_COMB.seq.*
28: /cgn2_6/ptodata/1/pna/US096B_COMB.seq.*
29: /cgn2_6/ptodata/1/pna/US096C_COMB.seq.*
30: /cgn2_6/ptodata/1/pna/US096D_COMB.seq.*
31: /cgn2_6/ptodata/1/pna/US096E_COMB.seq.*
32: /cgn2_6/ptodata/1/pna/US097A_COMB.seq.*
33: /cgn2_6/ptodata/1/pna/US097B_COMB.seq.*
34: /cgn2_6/ptodata/1/pna/US097C_COMB.seq.*
35: /cgn2_6/ptodata/1/pna/US098A_COMB.seq.*
36: /cgn2_6/ptodata/1/pna/US098B_COMB.seq.*
37: /cgn2_6/ptodata/1/pna/US098C_COMB.seq.*
38: /cgn2_6/ptodata/1/pna/US098D_COMB.seq.*
39: /cgn2_6/ptodata/1/pna/US099A_COMB.seq.*
40: /cgn2_6/ptodata/1/pna/US099B_COMB.seq.*
41: /cgn2_6/ptodata/1/pna/US099C_COMB.seq.*
42: /cgn2_6/ptodata/1/pna/US099D_COMB.seq.*
43: /cgn2_6/ptodata/1/pna/US099E_COMB.seq.*

44: /cgn2_6/ptodata/1/pna/US099F_COMB.seq.*
45: /cgn2_6/ptodata/1/pna/US099G_COMB.seq.*
46: /cgn2_6/ptodata/1/pna/US100A_COMB.seq.*
47: /cgn2_6/ptodata/1/pna/US100B_COMB.seq.*
48: /cgn2_6/ptodata/1/pna/US101A_COMB.seq.*
49: /cgn2_6/ptodata/1/pna/US101B_COMB.seq.*
50: /cgn2_6/ptodata/1/pna/US102A_COMB.seq.*
51: /cgn2_6/ptodata/1/pna/US102B_COMB.seq.*
52: /cgn2_6/ptodata/1/pna/US103A_COMB.seq.*
53: /cgn2_6/ptodata/1/pna/US103B_COMB.seq.*
54: /cgn2_6/ptodata/1/pna/US104A_COMB.seq.*
55: /cgn2_6/ptodata/1/pna/US104B_COMB.seq.*
56: /cgn2_6/ptodata/1/pna/US105A_COMB.seq.*
57: /cgn2_6/ptodata/1/pna/US105B_COMB.seq.*
58: /cgn2_6/ptodata/1/pna/US106A_COMB.seq.*
59: /cgn2_6/ptodata/1/pna/US107A_COMB.seq.*
60: /cgn2_6/ptodata/1/pna/US107B_COMB.seq.*
61: /cgn2_6/ptodata/1/pna/US107C_COMB.seq.*
62: /cgn2_6/ptodata/1/pna/US107D_COMB.seq.*
63: /cgn2_6/ptodata/1/pna/US108A_COMB.seq.*
64: /cgn2_6/ptodata/1/pna/US108B_COMB.seq.*
65: /cgn2_6/ptodata/1/pna/US109A_COMB.seq.*
66: /cgn2_6/ptodata/1/pna/US109B_COMB.seq.*
67: /cgn2_6/ptodata/1/pna/US109C_COMB.seq.*
68: /cgn2_6/ptodata/1/pna/US110_COMB.seq.*
69: /cgn2_6/ptodata/1/pna/US6000_COMB.seq.*
70: /cgn2_6/ptodata/1/pna/US6001_COMB.seq.*
71: /cgn2_6/ptodata/1/pna/US6002_COMB.seq.*
72: /cgn2_6/ptodata/1/pna/US6003_COMB.seq.*
73: /cgn2_6/ptodata/1/pna/US6004_COMB.seq.*
74: /cgn2_6/ptodata/1/pna/US6005_COMB.seq.*
75: /cgn2_6/ptodata/1/pna/US6006_COMB.seq.*
76: /cgn2_6/ptodata/1/pna/US6007_COMB.seq.*
77: /cgn2_6/ptodata/1/pna/US6008_COMB.seq.*
78: /cgn2_6/ptodata/1/pna/US6009_COMB.seq.*
79: /cgn2_6/ptodata/1/pna/US6010_COMB.seq.*
80: /cgn2_6/ptodata/1/pna/US6011_COMB.seq.*
81: /cgn2_6/ptodata/1/pna/US6012_COMB.seq.*
82: /cgn2_6/ptodata/1/pna/US6013_COMB.seq.*
83: /cgn2_6/ptodata/1/pna/US6014_COMB.seq.*
84: /cgn2_6/ptodata/1/pna/US6015_COMB.seq.*
85: /cgn2_6/ptodata/1/pna/US6016_COMB.seq.*
86: /cgn2_6/ptodata/1/pna/US6017_COMB.seq.*
87: /cgn2_6/ptodata/1/pna/US6018_COMB.seq.*
88: /cgn2_6/ptodata/1/pna/US6019_COMB.seq.*
89: /cgn2_6/ptodata/1/pna/US6020_COMB.seq.*
90: /cgn2_6/ptodata/1/pna/US6021_COMB.seq.*
91: /cgn2_6/ptodata/1/pna/US6022_COMB.seq.*
92: /cgn2_6/ptodata/1/pna/US6023A_COMB.seq.*
93: /cgn2_6/ptodata/1/pna/US6023B_COMB.seq.*
94: /cgn2_6/ptodata/1/pna/US6024_COMB.seq.*
95: /cgn2_6/ptodata/1/pna/US6025_COMB.seq.*
96: /cgn2_6/ptodata/1/pna/US6026_COMB.seq.*
97: /cgn2_6/ptodata/1/pna/US6027_COMB.seq.*
98: /cgn2_6/ptodata/1/pna/US6028_COMB.seq.*
99: /cgn2_6/ptodata/1/pna/US6029_COMB.seq.*
100: /cgn2_6/ptodata/1/pna/US6030_COMB.seq.*
101: /cgn2_6/ptodata/1/pna/US6031_COMB.seq.*
102: /cgn2_6/ptodata/1/pna/US6032_COMB.seq.*
103: /cgn2_6/ptodata/1/pna/US6033_COMB.seq.*
104: /cgn2_6/ptodata/1/pna/US6034_COMB.seq.*
105: /cgn2_6/ptodata/1/pna/US6035_COMB.seq.*
106: /cgn2_6/ptodata/1/pna/US6036_COMB.seq.*
107: /cgn2_6/ptodata/1/pna/US6037_COMB.seq.*
108: /cgn2_6/ptodata/1/pna/US6038_COMB.seq.*
109: /cgn2_6/ptodata/1/pna/US6039_COMB.seq.*
110: /cgn2_6/ptodata/1/pna/US6040_COMB.seq.*
111: /cgn2_6/ptodata/1/pna/US6041_COMB.seq.*
112: /cgn2_6/ptodata/1/pna/US6042_COMB.seq.*
113: /cgn2_6/ptodata/1/pna/US6043_COMB.seq.*
114: /cgn2_6/ptodata/1/pna/US6044_COMB.seq.*
115: /cgn2_6/ptodata/1/pna/US6045_COMB.seq.*
116: /cgn2_6/ptodata/1/pna/US6046_COMB.seq.*

FILE REFERENCE: 400/131 (MBH02-742-F)
CURRENT APPLICATION NUMBER: US/10/665,951
CURRENT FILING DATE: 2003-09-18
PRIOR APPLICATION NUMBER: US 10/664,668
PRIOR FILING DATE: 2003-09-18
PRIOR APPLICATION NUMBER: PCT/US 03/05022
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/399,348
PRIOR FILING DATE: 2002-07-29
PRIOR APPLICATION NUMBER: US 60/393,796
PRIOR FILING DATE: 2002-07-03
PRIOR APPLICATION NUMBER: US 10/287,949
PRIOR FILING DATE: 2002-11-04
PRIOR APPLICATION NUMBER: US 10/306,747
PRIOR FILING DATE: 2002-11-27
PRIOR APPLICATION NUMBER: PCT/US 02/17674
PRIOR FILING DATE: 2002-05-29
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 10/287,949
PRIOR FILING DATE: 2002-11-04
PRIOR APPLICATION NUMBER: US 10/306,747
PRIOR FILING DATE: 2002-11-27
PRIOR APPLICATION NUMBER: PCT/US 02/17674
PRIOR FILING DATE: 2002-05-29
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
PRIOR APPLICATION NUMBER: US 60/386,782
PRIOR FILING DATE: 2002-06-06
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 2455
SOFTWARE: PatentIn version 3.2
SEQ ID NO 2313
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: X stands for nitroindole universal base
US-10-665-951-2313

Query Match 90.5%; Score 19; DB 58; Length 19;
Best Local Similarity 78.9%; Pred. No. 12;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Oy 1 CUGAGUUUAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1
RESULT 3
US-10-758-155-2313/c
Sequence 2313, Application US/10758155
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwiggen, James
APPLICANT: Beigelman, Leonid
APPLICANT: Pavco, Pamela
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
FILE REFERENCE: 400/141 (MBH02742-N)
CURRENT APPLICATION NUMBER: US/10/758,155
CURRENT FILING DATE: 2004-01-12
PRIOR APPLICATION NUMBER: US 10/665,951
PRIOR FILING DATE: 2003-09-18
PRIOR APPLICATION NUMBER: US 10/664,668
PRIOR FILING DATE: 2003-09-18
PRIOR APPLICATION NUMBER: PCT/US 03/05022
PRIOR FILING DATE: 2003-02-20
PRIOR APPLICATION NUMBER: US 60/399,348
PRIOR FILING DATE: 2002-07-29

PRIOR APPLICATION NUMBER: US 60/393,796
PRIOR FILING DATE: 2002-07-03
PRIOR APPLICATION NUMBER: US 10/287,949
PRIOR FILING DATE: 2002-11-04
PRIOR APPLICATION NUMBER: US 10/306,747
PRIOR FILING DATE: 2002-11-27
PRIOR APPLICATION NUMBER: PCT/US 02/17674
PRIOR FILING DATE: 2002-05-29
PRIOR APPLICATION NUMBER: US 60/358,580
PRIOR FILING DATE: 2002-02-20
PRIOR APPLICATION NUMBER: US 60/363,124
PRIOR FILING DATE: 2002-03-11
Remaining Prior Application data removed - See File Wrapper or PALM.
NUMBER OF SEQ ID NOS: 2751
SOFTWARE: PatentIn version 3.3
SEQ ID NO 2313
LENGTH: 19
TYPE: RNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
FEATURE:
NAME/KEY: misc feature
LOCATION: (20)..(20)
OTHER INFORMATION: X stands for nitroindole universal base
US-10-758-155-2313

Query Match 90.5%; Score 19; DB 62; Length 19;
Best Local Similarity 78.9%; Pred. No. 12;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Oy 1 CUGAGUUUAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1
RESULT 4
US-10-831-620-2313/c
Sequence 2313, Application US/10831620
GENERAL INFORMATION:
APPLICANT: Sirna Therapeutics, Inc.
APPLICANT: McSwiggen, James
APPLICANT: Beigelman, Leonid
APPLICANT: Pavco, Pamela
TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
FILE REFERENCE: 400/152 (MBH02-742-Q)
CURRENT APPLICATION NUMBER: US/10/831,620
CURRENT FILING DATE: 2004-04-23
PRIOR APPLICATION NUMBER: US 10/764,957
PRIOR FILING DATE: 2004-01-26
PRIOR APPLICATION NUMBER: US 10/757,803
PRIOR FILING DATE: 2004-01-14
PRIOR APPLICATION NUMBER: US 10/758,155
PRIOR FILING DATE: 2004-01-12
PRIOR APPLICATION NUMBER: US 10/720,448
PRIOR FILING DATE: 2003-11-24
PRIOR APPLICATION NUMBER: US 10/712,633
PRIOR FILING DATE: 2003-11-13
PRIOR APPLICATION NUMBER: US 10/693,059
PRIOR FILING DATE: 2003-10-23
PRIOR APPLICATION NUMBER: US 10/670,011
PRIOR FILING DATE: 2003-09-23
PRIOR APPLICATION NUMBER: US 10/665,951
PRIOR FILING DATE: 2003-09-18
PRIOR APPLICATION NUMBER: US 10/664,668
PRIOR FILING DATE: 2003-09-18
PRIOR APPLICATION NUMBER: US 10/665,255

```

; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2313

```

```

;
; OTHER INFORMATION: Description of Artificial Sequence:  s1NA antisense region
;
; FEATURE:
; NAME/KEY:  misc feature
; LOCATION:  (20)..(20)
;
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
;
; FEATURE:
; NAME/KEY:  misc feature
; LOCATION:  (20)..(20)
;
; OTHER INFORMATION: X stands for nitroindole universal base
;
US-10-831-620-2313

```

```

; NAME/KEY: misc_feature
; LOCATION: (20_-(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20_-(20)
; OTHER INFORMATION: X stands for nitroindole universal base
US-10-844-076-2313

```

Query Match	90.5%	Score 19;	DB 63;	Length 19;
Best Local Similarity	78.9%	Pred. No. 12;		
Matches 15:	Conservative	4;	Mismatches	0;
	Indels	0;	Gaps	0;

```

;
; OTHER INFORMATION: DESCRIPTION OF ARTIFICIAL SEQUENCE: BINA ANCISENSE REGION
;
; FEATURE:

```

Query Match 90.5%; Score 19; DB 2; Length 21;

Best Local Similarity 100.0%; Pred. No. 13;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAGGCACCC 19
|||||
Db 1 CUGAGUUUAAAGGCACCC 19

RESULT 7

PCT-US03-05028-394/c

; Sequence 394, Application PC/TUS0305028

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; APPLICANT: Beigelman, Leonid

; APPLICANT: Chowrira, Bharat

; APPLICANT: Pavco, Pamela

; APPLICANT: Fosnaugh, Kathy

; APPLICANT: Jamison, Sharon

; APPLICANT: Usman, Nassim

; APPLICANT: Thompson, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using

; FILE REFERENCE: 400/104 (MBHB 03-198)

; CURRENT APPLICATION NUMBER: PCT/US03/05028

; CURRENT FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 60/406,784

; PRIOR FILING DATE: 2002-08-29

; PRIOR APPLICATION NUMBER: US 60/408,378

; PRIOR FILING DATE: 2002-09-05

; PRIOR APPLICATION NUMBER: US 60/409,293

; PRIOR FILING DATE: 2002-09-09

; PRIOR APPLICATION NUMBER: US 60/440,129

; PRIOR FILING DATE: 2003-01-15

; NUMBER OF SEQ ID NOS: 932

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 394

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (1)..(5)

; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (20)..(21)

; OTHER INFORMATION: n stands for thymidine

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (20)..(20)

; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage

PCT-US03-05028-394

Query Match

Best Local Similarity 90.5%; Score 19; DB 2; Length 21;

Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAGGCACCC 19

|||||

Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 8

PCT-US03-05028-398

; Sequence 398, Application PC/TUS0305028

; GENERAL INFORMATION:

; APPLICANT: Sirna Therapeutics, Inc.

; APPLICANT: McSwiggen, James

; APPLICANT: Beigelman, Leonid

; APPLICANT: Chowrira, Bharat

; APPLICANT: Pavco, Pamela

; APPLICANT: Fosnaugh, Kathy

; APPLICANT: Jamison, Sharon

; APPLICANT: Usman, Nassim

; APPLICANT: Thompson, James

; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using

; FILE REFERENCE: 400/104 (MBHB 03-198)

; CURRENT APPLICATION NUMBER: PCT/US03/05028

; CURRENT FILING DATE: 2003-02-20

; PRIOR APPLICATION NUMBER: US 60/363,124

; PRIOR FILING DATE: 2002-03-11

; PRIOR APPLICATION NUMBER: US 60/358,580

; PRIOR FILING DATE: 2002-02-20

; PRIOR APPLICATION NUMBER: US 60/386,782

; PRIOR FILING DATE: 2002-06-06

; PRIOR APPLICATION NUMBER: US 60/406,784

; PRIOR FILING DATE: 2002-08-29

; PRIOR APPLICATION NUMBER: US 60/408,378

; PRIOR FILING DATE: 2002-09-05

; PRIOR APPLICATION NUMBER: US 60/409,293

; PRIOR FILING DATE: 2002-09-09

; PRIOR APPLICATION NUMBER: US 60/440,129

; PRIOR FILING DATE: 2003-01-15

; NUMBER OF SEQ ID NOS: 932

; SOFTWARE: PatentIn version 3.2

; SEQ ID NO 398

; LENGTH: 21

; TYPE: RNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (1)..(2)

; OTHER INFORMATION: 2'-deoxy-2'-fluoro

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (1)..(4)

; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (6)..(8)

; OTHER INFORMATION: 2'-deoxy-2'-fluoro

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (15)..(15)

; OTHER INFORMATION: 2'-deoxy-2'-fluoro

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (17)..(19)

; OTHER INFORMATION: 2'-deoxy-2'-fluoro

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (17)..(20)

; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage

; FEATURE:

; NAME/KEY: misc_feature

; LOCATION: (20)..(21)

; OTHER INFORMATION: n stands for thymidine

PCT-US03-05028-398

Query Match

Best Local Similarity 90.5%; Score 19; DB 2; Length 21;

Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy

1 CUGAGUUUAAAGGCACCC 19

```
Db      1  CUGAGUUUAAAAGGCACCC 19
|||||
RESULT 9
PCT-US03-05028-402/c
; Sequence 402, Application PC/TUS0305028
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Chowrira, Bharat
; APPLICANT: Pavco, Pamela
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Usman, Nassim
; APPLICANT: Thompson, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/104 (MBHB 03-198)
; CURRENT APPLICATION NUMBER: PCT/US03/05028
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 402
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
PCT-US03-05028-402
Query Match          90.5%; Score 19; DB 2; Length 21;
Best Local Similarity 78.9%; Pred. No. 13;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      1  CUGAGUUUAAAAGGCACCC 19
|||||
Db      19  CTGAGTTTAAAAGGCACCC 1
|||||
RESULT 10
PCT-US03-05028-447
; Sequence 447, Application PC/TUS0305028
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Chowrira, Bharat
; APPLICANT: Pavco, Pamela
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Usman, Nassim
; APPLICANT: Thompson, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/104 (MBHB 03-198)
; CURRENT APPLICATION NUMBER: PCT/US03/05028
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 447
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(21)
; OTHER INFORMATION: n stands for thymidine
PCT-US03-05028-447
Query Match          90.5%; Score 19; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1  CUGAGUUUAAAAGGCACCC 19
|||||
Db      1  CUGAGUUUAAAAGGCACCC 19
|||||
RESULT 11
PCT-US03-05028-450/c
; Sequence 450, Application PC/TUS0305028
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Chowrira, Bharat
; APPLICANT: Pavco, Pamela
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Usman, Nassim
; APPLICANT: Thompson, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/104 (MBHB 03-198)
; CURRENT APPLICATION NUMBER: PCT/US03/05028
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 447
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
PCT-US03-05028-447
```

; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 450
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
PCT-US03-05028-450

Query Match 90.5%; Score 19; DB 2; Length 21;
Best Local Similarity 78.9%; Pred. No. 13;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Oy 1 CUGAGUUUAAAAGGCACCC 19
|:||||:|||||
Db 19 CTGAGTTTAAAAGGCACCC 1

RESULT 12

PCT-US03-05028-453
; Sequence 453, Application PC/TUS0305028
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Chowrira, Bharat
; APPLICANT: Pavco, Pamela
; APPLICANT: Fossnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Usman, Nassim
; APPLICANT: Thompson, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/104 (MBHB 03-198)
; CURRENT APPLICATION NUMBER: PCT/US03/05028
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 453
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc_feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature

; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (6)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; NAME/KEY: misc_feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
PCT-US03-05028-453

Query Match 90.5%; Score 19; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Oy 1 CUGAGUUUAAAAGGCACCC 19
|:||||:|||||
Db 1 CUGAGUUUAAAAGGCACCC 19

RESULT 13

PCT-US03-05028-456/c
; Sequence 456, Application PC/TUS0305028
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Chowrira, Bharat
; APPLICANT: Pavco, Pamela
; APPLICANT: Fossnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Usman, Nassim
; APPLICANT: Thompson, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/104 (MBHB 03-198)
; CURRENT APPLICATION NUMBER: PCT/US03/05028
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 456
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region

```
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
PCT-US03-05028-456
```

```
Query Match 90.5%; Score 19; DB 2; Length 21;
Best Local Similarity 78.9%; Pred. No. 13;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 CUGAGUUUAAAAGGCACCC 19
|:||||:|||||
Db 19 CTGAGTTTAAAAGGCACCC 1
```

```
RESULT 14
PCT-US03-05028-459
; Sequence 459, Application PC/TUS0305028
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Chowrira, Bharat
; APPLICANT: Pavco, Pamela
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Usman, Nassim
; APPLICANT: Thompson, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/104 (MBHB 03-198)
; CURRENT APPLICATION NUMBER: PCT/US03/05028
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 459
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA sense region
; FEATURE:
; NAME/KEY: misc feature
```

```
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic mosity
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (3)..(5)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (9)..(14)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)..(16)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic mosity
PCT-US03-05028-459
```

```
Query Match 90.5%; Score 19; DB 2; Length 21;
Best Local Similarity 100.0%; Pred. No. 13;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 CUGAGUUUAAAAGGCACCC 19
|:||||:|||||
Db 1 CUGAGUUUAAAAGGCACCC 19
```

```
RESULT 15
PCT-US03-05028-462/c
; Sequence 462, Application PC/TUS0305028
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Chowrira, Bharat
; APPLICANT: Pavco, Pamela
; APPLICANT: Fosnaugh, Kathy
; APPLICANT: Jamison, Sharon
; APPLICANT: Usman, Nassim
; APPLICANT: Thompson, James
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Gene Expression Using
; FILE REFERENCE: 400/104 (MBHB 03-198)
; CURRENT APPLICATION NUMBER: PCT/US03/05028
; CURRENT FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
```

```
; PRIOR APPLICATION NUMBER: US 60/406,784
; PRIOR FILING DATE: 2002-08-29
; PRIOR APPLICATION NUMBER: US 60/408,378
; PRIOR FILING DATE: 2002-09-05
; PRIOR APPLICATION NUMBER: US 60/409,293
; PRIOR FILING DATE: 2002-09-09
; PRIOR APPLICATION NUMBER: US 60/440,129
; PRIOR FILING DATE: 2003-01-15
; NUMBER OF SEQ ID NOS: 932
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 462
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA antisense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
PCT-US03-05028-462

Query Match          90.5%; Score 19; DB 2; Length 21;
Best Local Similarity 78.9%; Pred. NO. 13;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      1  CUGAGUUUUAAGGCACCC 19
       |||:::|||
Db      19  CTGAGTTTAAAGGCACCC 1

Search completed: August 18, 2005, 23:33:06
Job time : 3830 secs
```

This Page Blank (uspto)

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 22:24:18 ; Search time 610 seconds.
(without alignments)
223.664 Million cell updates/sec

Title: US-10-665-951-2185
Perfect score: 21
Sequence: 1 cugaguuaaaaggcaccm 21

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 7316285 seqs, 3248459403 residues

Total number of hits satisfying chosen parameters: 7811414

Minimum DB seq length: 0
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Published Applications NA:*

- 1: /cgn2_6/ptodata/1/pubpna/US07_PUBCOMB.seq:*
- 2: /cgn2_6/ptodata/1/pubpna/PCT_NEW_PUB.seq:*
- 3: /cgn2_6/ptodata/1/pubpna/US06_NEW_PUB.seq:*
- 4: /cgn2_6/ptodata/1/pubpna/US06_PUBCOMB.seq:*
- 5: /cgn2_6/ptodata/1/pubpna/US07_NEW_PUB.seq:*
- 6: /cgn2_6/ptodata/1/pubpna/PCTUS_PUBCOMB.seq:*
- 7: /cgn2_6/ptodata/1/pubpna/US08_NEW_PUB.seq:*
- 8: /cgn2_6/ptodata/1/pubpna/US08_PUBCOMB.seq:*
- 9: /cgn2_6/ptodata/1/pubpna/US09A_PUBCOMB.seq:*
- 10: /cgn2_6/ptodata/1/pubpna/US09B_PUBCOMB.seq:*
- 11: /cgn2_6/ptodata/1/pubpna/US09C_PUBCOMB.seq:*
- 12: /cgn2_6/ptodata/1/pubpna/US09_NEW_PUB.seq:*
- 13: /cgn2_6/ptodata/1/pubpna/US10A_PUBCOMB.seq:*
- 14: /cgn2_6/ptodata/1/pubpna/US10B_PUBCOMB.seq:*
- 15: /cgn2_6/ptodata/1/pubpna/US10C_PUBCOMB.seq:*
- 16: /cgn2_6/ptodata/1/pubpna/US10D_PUBCOMB.seq:*
- 17: /cgn2_6/ptodata/1/pubpna/US10E_PUBCOMB.seq:*
- 18: /cgn2_6/ptodata/1/pubpna/US10F_PUBCOMB.seq:*
- 19: /cgn2_6/ptodata/1/pubpna/US10G_PUBCOMB.seq:*
- 20: /cgn2_6/ptodata/1/pubpna/US10H_PUBCOMB.seq:*
- 21: /cgn2_6/ptodata/1/pubpna/US10I_PUBCOMB.seq:*
- 22: /cgn2_6/ptodata/1/pubpna/US10J_PUBCOMB.seq:*
- 23: /cgn2_6/ptodata/1/pubpna/US11A_PUBCOMB.seq:*
- 24: /cgn2_6/ptodata/1/pubpna/US11_NEW_PUB.seq:*
- 25: /cgn2_6/ptodata/1/pubpna/US60_NEW_PUB.seq:*
- 26: /cgn2_6/ptodata/1/pubpna/US60_PUBCOMB.seq:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	19	90.5	19	US-10-665-951-2313	Sequence 2313, Ap
C 2	19	90.5	19	US-10-758-155-2313	Sequence 2313, Ap
C 3	19	90.5	19	US-10-831-620-2313	Sequence 2313, Ap
C 4	19	90.5	19	US-10-844-076-2313	Sequence 2313, Ap
C 5	19	90.5	21	US-10-665-951-2092	Sequence 2092, Ap
C 6	19	90.5	21	US-10-665-951-2096	Sequence 2096, Ap
C 7	19	90.5	21	US-10-665-951-2100	Sequence 2100, Ap

C 8	19	90.5	21	19	US-10-665-951-2104	Sequence 2104, Ap
C 9	19	90.5	21	19	US-10-665-951-2149	Sequence 2149, Ap
C 10	19	90.5	21	19	US-10-665-951-2152	Sequence 2152, Ap
C 11	19	90.5	21	19	US-10-665-951-2155	Sequence 2155, Ap
C 12	19	90.5	21	19	US-10-665-951-2158	Sequence 2158, Ap
C 13	19	90.5	21	19	US-10-665-951-2161	Sequence 2161, Ap
C 14	19	90.5	21	19	US-10-665-951-2164	Sequence 2164, Ap
C 15	19	90.5	21	19	US-10-665-951-2185	Sequence 2185, Ap
C 16	19	90.5	21	19	US-10-665-951-2188	Sequence 2188, Ap
C 17	19	90.5	21	19	US-10-665-951-2218	Sequence 2218, Ap
C 18	19	90.5	21	19	US-10-665-951-2220	Sequence 2220, Ap
C 19	19	90.5	21	19	US-10-665-951-2222	Sequence 2222, Ap
C 20	19	90.5	21	19	US-10-665-951-2224	Sequence 2224, Ap
C 21	19	90.5	21	19	US-10-665-951-2281	Sequence 2281, Ap
C 22	19	90.5	21	19	US-10-665-951-2282	Sequence 2282, Ap
C 23	19	90.5	21	19	US-10-444-853A-297	Sequence 297, App
C 24	19	90.5	21	19	US-10-444-853A-301	Sequence 301, App
C 25	19	90.5	21	19	US-10-444-853A-305	Sequence 305, App
C 26	19	90.5	21	19	US-10-444-853A-345	Sequence 345, App
C 27	19	90.5	21	19	US-10-444-853A-621	Sequence 621, App
C 28	19	90.5	21	19	US-10-444-853A-622	Sequence 622, App
C 29	19	90.5	21	21	US-10-757-803-297	Sequence 297, App
C 30	19	90.5	21	21	US-10-757-803-301	Sequence 301, App
C 31	19	90.5	21	21	US-10-757-803-305	Sequence 305, App
C 32	19	90.5	21	21	US-10-757-803-345	Sequence 345, App
C 33	19	90.5	21	21	US-10-757-803-621	Sequence 621, App
C 34	19	90.5	21	21	US-10-757-803-622	Sequence 622, App
C 35	19	90.5	21	21	US-10-826-966-297	Sequence 297, App
C 36	19	90.5	21	21	US-10-826-966-301	Sequence 301, App
C 37	19	90.5	21	21	US-10-826-966-305	Sequence 305, App
C 38	19	90.5	21	21	US-10-826-966-345	Sequence 345, App
C 39	19	90.5	21	21	US-10-826-966-621	Sequence 621, App
C 40	19	90.5	21	21	US-10-826-966-622	Sequence 622, App
C 41	19	90.5	21	21	US-10-758-155-2092	Sequence 2092, Ap
C 42	19	90.5	21	21	US-10-758-155-2096	Sequence 2096, Ap
C 43	19	90.5	21	21	US-10-758-155-2100	Sequence 2100, Ap
C 44	19	90.5	21	21	US-10-758-155-2104	Sequence 2104, Ap
C 45	19	90.5	21	21	US-10-758-155-2149	Sequence 2149, Ap

ALIGNMENTS

RESULT 1

US-10-665-951-2313/c
; Sequence 2313, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (MBH02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580

```
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2313
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
;
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: X stands for nitroindole universal base
;
; US-10-665-951-2313
```

```
Query Match          90.5%; Score 19; DB 19; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.2;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
```

```
Qy 1 CUGAGUUUAAAAGGCACCC 19
    |:|:|:|:|:|:|:|:|:|
Db 19 CTGAGTTTAAAGGCACCC 1
```

```
RESULT 2
US-10-758-155-2313/c
; Sequence 2313, Application US/10758155
; Publication No. US20050075304A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/141 (MBHB02742-N)
; CURRENT APPLICATION NUMBER: US/10/758,155
; CURRENT FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2313
; LENGTH: 19
```

```
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
;
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: X stands for nitroindole universal base
;
; US-10-758-155-2313

Query Match          90.5%; Score 19; DB 21; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.2;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
    |:|:|:|:|:|:|:|:|:|
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 3
US-10-831-620-2313/c
; Sequence 2313, Application US/10831620
; Publication No. US20050148530A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/152 (MBHB02-742-Q)
; CURRENT APPLICATION NUMBER: US/10/831,620
; CURRENT FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/665,255
; PRIOR FILING DATE: 2003-09-16
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2751
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2313
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
;
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
```

; LOCATION: (20)...(20)
; OTHER INFORMATION: X stands for nitroindole universal base
US-10-831-620-2313

Query Match 90.5%; Score 19; DB 22; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.2;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
|:||||:|||||
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 4
US-10-844-076-2313/c
; Sequence 2313, Application US/10844076
; Publication No. US20050171039A1
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/159 (MBHB02-742-R)
; CURRENT APPLICATION NUMBER: US/10/844,076
; CURRENT FILING DATE: 2004-05-11
; PRIOR APPLICATION NUMBER: US 10/831,620
; PRIOR FILING DATE: 2004-04-23
; PRIOR APPLICATION NUMBER: US 10/764,957
; PRIOR FILING DATE: 2004-01-26
; PRIOR APPLICATION NUMBER: US 10/757,803
; PRIOR FILING DATE: 2004-01-14
; PRIOR APPLICATION NUMBER: US 10/758,155
; PRIOR FILING DATE: 2004-01-12
; PRIOR APPLICATION NUMBER: US 10/720,448
; PRIOR FILING DATE: 2003-11-24
; PRIOR APPLICATION NUMBER: US 10/712,633
; PRIOR FILING DATE: 2003-11-13
; PRIOR APPLICATION NUMBER: US 10/693,059
; PRIOR FILING DATE: 2003-10-23
; PRIOR APPLICATION NUMBER: US 10/670,011
; PRIOR FILING DATE: 2003-09-23
; PRIOR APPLICATION NUMBER: US 10/665,951
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2755
; SOFTWARE: PatentIn version 3.3
; SEQ ID NO 2313
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)...(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)...(20)
; OTHER INFORMATION: X stands for nitroindole universal base
US-10-844-076-2313

Query Match 90.5%; Score 19; DB 22; Length 19;
Best Local Similarity 78.9%; Pred. No. 4.2;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
|:||||:|||||

Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 5

US-10-665-951-2092
; Sequence 2092, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siNA)
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2092
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)...(5)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)...(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)...(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
US-10-665-951-2092

Query Match 90.5%; Score 19; DB 19; Length 21;
Best Local Similarity 100.0%; Pred. No. 4.3;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
|:||||:|||||
Db 1 CUGAGUUUAAAAGGCACCC 19

RESULT 6
US-10-665-951-2096/c
; Sequence 2096, Application US/10665951


```
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2152
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA antisense region
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
US-10-665-951-2152

Query Match          90.5%; Score 19; DB 19; Length 21;
Best Local Similarity 78.9%; Pred. No. 4.3;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1 CUGAGUUUAAAAGGCACCC 19
   |||:::|||||
DB 19 CTGAGTTTAAAGGCACCC 1

RESULT 11
US-10-665-951-2155
; Sequence 2155, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
```

```
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2155
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siNA sense region
; NAME/KEY: misc feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3 attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3 attached terminal deoxyabasic moiety
US-10-665-951-2155

Query Match          90.5%; Score 19; DB 19; Length 21;
Best Local Similarity 100.0%; Pred. No. 4.3;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CUGAGUUUAAAAGGCACCC 19
   |||:::|||||
DB 1 CUGAGUUUAAAAGGCACCC 19

RESULT 12
US-10-665-951-2158/c
; Sequence 2158, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: 400/131 (MHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04
; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
```

```

; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2158
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (4)..(4)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(11)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(17)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(20)
; OTHER INFORMATION: Phosphorothioate 3'-Internucleotide Linkage
; US-10-665-951-2158

Query Match          90.5%; Score 19; DB 19; Length 21;
Best Local Similarity 78.9%; Pred. No. 4.3;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 19 CTGAGTTTAAAAGGCACCC 1

RESULT 13
US-10-665-951-2161
; Sequence 2161, Application US/10665951
; Publication No. US20040138163A1
; GENERAL INFORMATION:
; APPLICANT: Sirna Therapeutics, Inc.
; APPLICANT: McSwiggen, James
; APPLICANT: Beigelman, Leonid
; APPLICANT: Pavco, Pamela
; TITLE OF INVENTION: RNA Interference Mediated Inhibition of Vascular Endothelial
; TITLE OF INVENTION: Growth Factor and Vascular Endothelial Growth Factor Receptor
; TITLE OF INVENTION: Gene Expression Using Short Interfering Nucleic Acid (siRNA)
; FILE REFERENCE: 400/131 (MBHB02-742-F)
; CURRENT APPLICATION NUMBER: US/10/665,951
; CURRENT FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: US 10/664,668
; PRIOR FILING DATE: 2003-09-18
; PRIOR APPLICATION NUMBER: PCT/US 03/05022
; PRIOR FILING DATE: 2003-02-20
; PRIOR APPLICATION NUMBER: US 60/399,348
; PRIOR FILING DATE: 2002-07-29
; PRIOR APPLICATION NUMBER: US 60/393,796
; PRIOR FILING DATE: 2002-07-03
; PRIOR APPLICATION NUMBER: US 10/287,949
; PRIOR FILING DATE: 2002-11-04

```

```

; PRIOR APPLICATION NUMBER: US 10/306,747
; PRIOR FILING DATE: 2002-11-27
; PRIOR APPLICATION NUMBER: PCT/US 02/17674
; PRIOR FILING DATE: 2002-05-29
; PRIOR APPLICATION NUMBER: US 60/358,580
; PRIOR FILING DATE: 2002-02-20
; PRIOR APPLICATION NUMBER: US 60/363,124
; PRIOR FILING DATE: 2002-03-11
; PRIOR APPLICATION NUMBER: US 60/386,782
; PRIOR FILING DATE: 2002-06-06
; Remaining Prior Application data removed - See File Wrapper or PALM.
; NUMBER OF SEQ ID NOS: 2455
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2161
; LENGTH: 21
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: siRNA sense region
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(2)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(1)
; OTHER INFORMATION: 5'-3' attached terminal deoxyabasic moiety
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (3)..(5)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (6)..(8)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (9)..(14)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (15)..(15)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (16)..(16)
; OTHER INFORMATION: 2'-deoxy
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (17)..(19)
; OTHER INFORMATION: 2'-deoxy-2'-fluoro
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (20)..(21)
; OTHER INFORMATION: n stands for thymidine
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (21)..(21)
; OTHER INFORMATION: 3'-3' attached terminal deoxyabasic moiety
; US-10-665-951-2161

Query Match          90.5%; Score 19; DB 19; Length 21;
Best Local Similarity 100.0%; Pred. No. 4.3;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19
Db 1 CUGAGUUUAAAAGGCACCC 19

RESULT 14
US-10-665-951-2164/c
; Sequence 2164, Application US/10665951

```


GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 21:39:47 ; Search time 124 Seconds
(without alignments)
277.111 Million cell updates/sec

Title: US-10-665-951-2185
Perfect score: 21
Sequence: 1 cugaguuaaaaggacccnn 21

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 1202784 seqs, 818138359 residues

Total number of hits satisfying chosen parameters: 970836

Minimum DB seq length: 0
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents NA.*
1: /cgn2_6/ptodata/1/ina/5A_COMB.seq.*
2: /cgn2_6/ptodata/1/ina/5B_COMB.seq.*
3: /cgn2_6/ptodata/1/ina/6A_COMB.seq.*
4: /cgn2_6/ptodata/1/ina/6B_COMB.seq.*
5: /cgn2_6/ptodata/1/ina/PTUS_COMB.seq.*
6: /cgn2_6/ptodata/1/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	17	81.0	17	3	US-08-584-040-1494
2	17	81.0	17	3	US-08-584-040-7243
3	17	81.0	17	4	US-09-371-772B-39
4	17	81.0	17	4	US-09-685-664B-39
5	17	81.0	20	4	US-09-953-318-24
6	16	76.2	17	3	US-08-584-040-1493
7	16	76.2	17	3	US-08-584-040-7242
8	16	76.2	17	4	US-09-371-772B-38
9	16	76.2	17	4	US-09-685-664B-38
10	16	76.2	20	4	US-09-953-318-25
11	15	71.4	17	3	US-08-584-040-1492
12	15	71.4	17	3	US-08-584-040-7241
13	15	71.4	17	4	US-09-371-772B-37
14	15	71.4	17	4	US-09-685-664B-37
15	13.2	62.9	25	4	US-09-396-196G-30680
16	13.2	62.9	25	4	US-09-396-196G-30689
17	13.2	62.9	30	1	US-07-832-905B-86
18	13.2	62.9	30	2	US-08-700-757-86
19	12.8	61.0	19	4	US-09-422-978-9871
20	12.8	61.0	25	4	US-09-396-196G-44902
21	12.6	60.0	21	4	US-09-060-299-116
22	12.6	60.0	21	4	US-09-402-923A-116
23	12.4	59.0	22	4	US-09-032-438C-77
24	12.4	58.1	25	4	US-09-396-196G-18378
25	12.2	58.1	25	4	US-09-396-196G-30679
26	12.2	58.1	25	4	US-09-396-196G-106340
27	12.2	58.1	26	2	US-08-687-080-162

28	12.2	58.1	26	2	US-08-859-998-566	Sequence 566, App
29	12.2	58.1	26	3	US-09-225-928-566	Sequence 566, App
30	12.2	58.1	26	4	US-09-225-201B-566	Sequence 566, App
C 31	12.2	58.1	30	2	US-08-629-001A-68	Sequence 68, Appl
C 32	12.2	58.1	30	3	US-08-513-974B-137	Sequence 137, Appl
C 33	12.2	58.1	30	3	US-08-642-274D-147	Sequence 147, Appl
34	12	57.1	17	4	US-09-371-772B-4222	Sequence 4222, Ap
35	12	57.1	28	3	US-08-877-966B-8	Sequence 8, Appli
36	11.8	56.2	17	3	US-09-080-044-15	Sequence 15, Appl
37	11.8	56.2	17	3	US-09-531-857A-15	Sequence 15, Appl
C 38	11.8	56.2	19	4	US-09-422-978-6473	Sequence 6473, Ap
C 39	11.8	56.2	21	3	US-09-080-044-14	Sequence 14, Appl
C 40	11.8	56.2	21	3	US-09-531-857A-14	Sequence 14, Appl
C 41	11.8	56.2	22	3	US-08-771-623-3	Sequence 3, Appli
C 42	11.8	56.2	22	3	US-09-376-097-14	Sequence 14, Appli
C 43	11.8	56.2	22	4	US-08-965-492-1	Sequence 1, Appli
C 44	11.8	56.2	22	4	US-09-732-279-3	Sequence 3, Appli
C 45	11.8	56.2	25	3	US-08-771-623-27	Sequence 27, Appl

ALIGNMENTS

RESULT 1
US-08-584-040-1494
; Sequence 1494, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggan, James
; APPLICANT: Stichcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1494:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-584-040-1494

Query Match 81.0%; Score 17; DB 3; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.6;
Matches 17; Conservative 0; Mismatches 0; Indels

Qy 1 CUGAGUUTUAAAAGGCAC 17
|||
D'b 1 CUGAGUUTUAAAAGGCAC 17

RESULT 2

```

US-08-584-040-7243
; Sequence 7243, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

```

Query Match 81.0%; Score 17; DB 3; Length 17;
Best Local Similarity 100.0%; Pred. No. 7.6;
Matches 17; Conservative 0; Mismatches 0; Indels

Qy 1 CUGAGUUUAAAAGGCAC 17
|||||

Dh 1 CUGAGUUUAAAAGGCAC 17
|||||

RESULT 3

```

US-09-371-772B-39
; Sequence 39, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McGswiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for
; TITLE OF INVENTION: Levels of Vascular En
; FILE REFERENCE: MEHBOO,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 39
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-39

```

Query Match 81.0%; Score 17; DB 4;
Best Local Similarity 100.0%; Pred. No. 7.6;
Matches 17; Conservative 0; Mismatches 0; Indels

Qy 1 CUGAGUUA AAAGGCAC 17
|||||

pB 1 CUGAGUUA AAAGGCAC 17

RESULT 4

```

US-09-685-664B-39
; Sequence 39, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for
; FILE REFERENCE: MHB00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 39
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-39

```

Query Match	81.0%;	Score 17;	DB 4;	Length 17;
Best Local Similarity	100.0%;	Pred. No. 7.6;		
Matches 17; Conservative	0;	Mismatches 0;	Indels 0;	Gaps 0;

Qy 1 CUGAGUTUAAAAGGCAC 17
|||
Db 1 CUGAGUTUAAAAGGCAC 17

```
RESULT 5
US-09-953-318-24/c
; Sequence 24, Application US/09953318
; Patent No. 6710174
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR EXPRESSION
; FILE REFERENCE: RTS-0232
; CURRENT APPLICATION NUMBER: US/09/953.318
; CURRENT FILING DATE: 2001-09-13
; NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 24
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-953-318-24
Query Match      81.0%; Score 17; DB 4; Length 20;
Best Local Similarity 76.5%; Pred. No. 7.8;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy      1 CUGAGUUUAAAAGGCAC 17
Db      17 CTGAGTTTAAAAGGCAC 1

RESULT 6
US-08-584-040-1493
; Sequence 1493, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440

Query Match      76.2%; Score 16; DB 3; Length 17;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

RESULT 7
US-08-584-040-7242
; Sequence 7242, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440

Query Match      76.2%; Score 16; DB 3; Length 17;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

```
TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1493:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-1493
Query Match      76.2%; Score 16; DB 3; Length 17;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1 CUGAGUUUAAAAGGCAC 16
Db      2 CUGAGUUUAAAAGGCAC 17

RESULT 7
US-08-584-040-7242
; Sequence 7242, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440

Query Match      76.2%; Score 16; DB 3; Length 17;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
```

QY 1 CUGAGUUUAAAAGGCA 16
|||||
Db 2 CUGAGUUUAAAAGGCA 17

RESULT 8

US-09-371-772B-38
; Sequence 38, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 38
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-38

Query Match 76.2%; Score 16; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 27;
Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 CUGAGUUUAAAAGGCA 16
|||||
Db 2 CUGAGUUUAAAAGGCA 17

RESULT 9

US-09-685-664B-38
; Sequence 38, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Related to Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 38
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-38

Query Match 76.2%; Score 16; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 27;

Matches 16; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1 CUGAGUUUAAAAGGCA 16
|||||
Db 2 CUGAGUUUAAAAGGCA 17

RESULT 10

US-09-953-318-25/c
; Sequence 25, Application US/09953318
; Patent No. 6710174
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR
; TITLE OF INVENTION: EXPRESSION
; FILE REFERENCE: RTS-0232
; CURRENT APPLICATION NUMBER: US/09/953,318
; CURRENT FILING DATE: 2001-09-13
; NUMBER OF SEQ ID NOS: 154
; SEQ ID NO 25
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-953-318-25

Query Match 76.2%; Score 16; DB 4; Length 20;
Best Local Similarity 81.2%; Pred. No. 27;
Matches 13; Conservative 3; Mismatches 0; Indels 0; Gaps 0;

QY 4 AGUUUAAAAGGCACCC 19
|:::|
Db 20 AGTTTAAAAGGCACCC 5

RESULT 11

US-08-584-040-1492
; Sequence 1492, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF DISEASES OR CONDITIONS RELATED TO VASCULAR ENDOTHELIAL GROWTH FACTOR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS OF VASCULAR ENDOTHELIAL GROWTH FACTOR
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995

```
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1492:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-1492

Query Match 71.4%; Score 15; DB 3; Length 17;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGC 15
Db 3 CUGAGUUUAAAAGGC 17

RESULT 12
US-08-584-040-7241
; Sequence 7241, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESSES:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7241:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
```

```
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7241

Query Match 71.4%; Score 15; DB 3; Length 17;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGC 15
Db 3 CUGAGUUUAAAAGGC 17

RESULT 13
US-09-371-772B-37
; Sequence 37, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 37
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-37

Query Match 71.4%; Score 15; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGC 15
Db 3 CUGAGUUUAAAAGGC 17

RESULT 14
US-09-685-664B-37
; Sequence 37, Application US/09685664B
; Patent No. 6818447
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for Treatment of Diseases or Conditions Relate
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00-876-K (400/021)
; CURRENT APPLICATION NUMBER: US/09/685,664B
; CURRENT FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; PRIOR APPLICATION NUMBER: US 09/371,772
; PRIOR FILING DATE: 1999-08-10
; NUMBER OF SEQ ID NOS: 8231
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 37
```

```

; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-685-664B-37

```

Query Match 71.4%; Score 15; DB 4; Length 17;
Best Local Similarity 100.0%; Pred. No. 93;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGC 15
Db 3 CUGAGUUUAAAAGGC 17

```

RESULT 15
US-09-396-196G-30680
; Sequence 30680, Application US/09396196G
; Patent No. 6821724
; GENERAL INFORMATION:
; APPLICANT: Michael Mittmann
; APPLICANT: David Mack
; APPLICANT: David Lockhart
; APPLICANT: Affymetrix, Inc.
; TITLE OF INVENTION: Methods of Genetic Analysis
; FILE REFERENCE: 3101.1
; CURRENT APPLICATION NUMBER: US/09/396.196G
; CURRENT FILING DATE: 1999-09-15
; PRIOR APPLICATION NUMBER: 60/100,678
; PRIOR FILING DATE: 1998-09-17
; NUMBER OF SEQ ID NOS: 127806
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 30680
; LENGTH: 25
; TYPE: DNA
; ORGANISM: Mus musculus
US-09-396-196G-30680

```

```
Query Match          62.9%; Score 13.2; DB 4; Length 25;
Best Local Similarity 66.7%; Pred. NO. 9.4e+02;
Matches 12; Conservative 3; Mismatches 3; Indels 0; Gaps 0;
```

Qy 1 CUGAGUUTUAAAAGGCACC 18
 | : | | : | | | | |
Db 8 CTGAGTTCAGGAGGCACC 25

Search completed: August 18, 2005, 22:27:29
Job time : 125 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 23:33:14 ; Search time 2976 Seconds
(without alignments)
268.599 Million cell updates/sec

Title: US-10-665-951-2185
Perfect score: 21
Sequence: 1 cugaguuaaaaggcaccnn 21

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 34239544 seqs, 19032134700 residues

Total number of hits satisfying chosen parameters: 46888

Minimum DB seq length: 0
Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : EST:
1: gb_est1.*
2: gb_est2.*
3: gb_hcc.*
4: gb_est3.*
5: gb_est4.*
6: gb_est5.*
7: gb_est6.*
8: gb_gss1.*
9: gb_gss2.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	12.2	58.1	30	8	AZ309241 IM0013106
C 2	11.6	55.2	27	6	CD532363 26011 Ara
C 3	11.6	55.2	27	9	AG204232 Pan trogl
C 4	11.4	54.3	20	9	AG189412 Pan trogl
C 5	11.2	53.3	30	9	CC887301 SALK 1499
C 6	10.8	51.4	30	8	AZ804304 2M0065M14
C 7	10.6	50.5	20	8	AZ864535 2M0174J12
C 8	10.6	50.5	25	8	AZ397442 1M0162K11
C 9	10.6	50.5	25	8	AZ792292 2M0043H11
C 10	10.6	50.5	28	9	AJ588176 Arabidops
C 11	10.4	49.5	23	9	AL464277 T. brucei
C 12	10.4	49.5	24	1	AJ258068 AU258068
C 13	10.4	49.5	24	8	AZ660125 1M0538F04
C 14	10.4	49.5	29	8	AZ457829 1M0261C20
C 15	10.4	49.5	29	8	AZ813693 2M0081P03
C 16	10.2	48.6	19	1	AI678558 tu83h07.x
C 17	10.2	48.6	19	8	AZ428450 1M0210024
C 18	10.2	48.6	20	8	AZ368997 1M0119B20
C 19	10.2	48.6	22	9	AL452318 T. brucei
C 20	10.2	48.6	23	9	CT793275 SALK 0126
C 21	10.2	48.6	25	8	AZ583031 1M0376C15
C 22	10.2	48.6	25	8	AZ785568 2M0029K02
C 23	10.2	48.6	25	9	X88105 H.sapiens D
C 24	10.2	48.6	26	8	AZ445641 1M0241L05

C 25	10.2	48.6	30	1	AL585483
C 26	10	47.6	23	8	AZ387817
C 27	10	47.6	23	8	AZ584523
C 28	10	47.6	25	1	AU254095
C 29	10	47.6	25	8	AZ789794
C 30	10	47.6	26	8	AZ783417
C 31	10	47.6	27	7	D19150
C 32	10	47.6	27	8	AZ470253
C 33	10	47.6	28	8	AZ535595
C 34	10	47.6	29	8	AZ640466
C 35	10	47.6	29	8	AZ966795
C 36	10	47.6	30	9	TA7F10Q
C 37	9.8	46.7	19	8	AZ410166
C 38	9.8	46.7	19	8	AZ659603
C 39	9.8	46.7	20	1	AU254453
C 40	9.8	46.7	21	7	CO789498
C 41	9.8	46.7	22	8	AZ424233
C 42	9.8	46.7	23	8	AZ796147
C 43	9.8	46.7	25	1	AU007217
C 44	9.8	46.7	26	4	BM400078
C 45	9.8	46.7	26	8	AZ514488

ALIGNMENTS

RESULT 1
AZ309241/c
LOCUS
DEFINITION
AZ309241
VERSION
KEYWORDS
SOURCE
ORGANISM
REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

AZ309241 30 bp DNA linear GSS 29-SEP-2000
1M0013106F Mouse 10kb plasmid UUC1M library Mus musculus genomic
Clone UUC1M0013106 F, genomic survey sequence.

ACCESSION
VERSION
KEYWORDS
SOURCE
ORGANISM

AZ309241
GI:10350030
GSS.
Mus musculus (house mouse)

REFERENCE
AUTHORS
TITLE
JOURNAL
COMMENT

1 (bases 1 to 30)
Dunn, D., Aoyagi, A., Barber, M., Beacorn, T., Duval, B., Hamil, C.,
Islam, H., Longacre, S., Mahmoud, M., Meenen, E., Pedersen, T.,
Reilly, M., Rose, M., Rose, R., Stokes, R., Tingey, A., von
Niederhausern, A. and Wright, D., Weiss, R.,
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
University of Utah
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0013 row: 1 column: 06
Seq primer: CGTTGTAAACACGCGCCAGT
Class: plasmid ends
High quality sequence stop: 30.
Location/Qualifiers
1..30
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
/db_xref="taxon:10090"
/clone="UUC1M0013106"
/sex="Male"
/lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUC1M library"
/note="Vector: PWD42nv; Purified genomic DNA from M.
musculus C57BL/6J (male) was obtained from the Jackson
Laboratory Mouse DNA Resource
(http://www.jax.org/resources/documents/dnares/). The DNA


```

REFERENCE
AUTHORS      Park,H., Kim,Y., Kim,S., Han,Y., Woo,T., Park,K., Eun,C.J.,
              Hoon,S.T., Chu,M., Kim,H., Joo,S., Kim,C., Song,W. and Yoo,H.
TITLE        BAC end sequences of Library RP-43
REFERENCE
AUTHORS      Park,H., Kim,Y., Kim,S., Han,Y., Woo,T., Park,K., Eun,C.J.,
              Hoon,S.T., Chu,M., Kim,H., Joo,S., Kim,C., Song,W. and Yoo,H.
TITLE        Direct Submission
JOURNAL      Submitted (07-JAN-2002) Hong-Seog Park, Korea Research Institute of
              Bioscience and Biotechnology (KRIBB), Genome Research Center (GRC);
              52, Oun-dong, Yusong-gu, Daejeon 305-333, Korea
              (E-mail:redstone@kribb.re.kr, URL:http://pds.grc.kribb.re.kr/,
              Tel:82-42-866-7181, Fax:82-42-860-4409)
COMMENT      Clones are derived from the chimpanzee BAC library RP-43 This BAC
              end was generated during the R&D process and may have higher chance
              of clone tracking errors.
PRIMERS
Sequencing: T3
LIBRARY
Vector       : pBACe3.6
R.Site 1     : EORI
R.Site 2     : EORI
FEATURES
source      Location/Qualifiers
              1..20
              /organism="Pan troglodytes"
              /mol_type="genomic DNA"
              /db_xref="taxon:9598"
              /clone="RP43-063018.TJ"
              /sex="male"
              /cell_type="lymphocytes"
              /clone_lib="RP-43 Chimpanzee Male BAC Library"
ORIGIN
Query Match      54.3%; Score 11.4; DB 9; Length 20;
Best Local Similarity 61.5%; Pred. No. 5.3e+05;
Matches 8; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

Qy      1 CUGAGUUUAAAAG 13
        ||| :|||||
Db      2 CTGACTTTAAAAG 14

RESULT 5
CC887301
LOCUS     SALK_149938 31.65 x Arabidopsis thaliana TDNA insertion lines
DEFINITION Arabidopsis thaliana genomic clone SALK_149938.31.65.x, genomic
            survey sequence.
ACCESSION CC887301
VERSION   CC887301.1 GI:33363657
KEYWORDS  GSS.
SOURCE    Arabidopsis thaliana (thale cress)
ORGANISM  Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
            Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
            rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
REFERENCE
AUTHORS      Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R.,
              Gadrinab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L.,
              Shinn,P., Zimmerman,J. and Ecker,J.R.
TITLE        A Sequence-Indexed Library of Insertion Mutations in the
JOURNAL      Arabidopsis Genome
COMMENT      Unpublished (2001)
            Contact: Joseph R. Ecker
            Salk Institute Genomic Analysis Laboratory (SIGnAL)
            10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
            Tel: 858 453 4100 x1752
            Fax: 858 558 6379
            Email: ecker@salk.edu
            This is single pass sequence recovered from the left border of

```

```

TDNA.
Class: TDNA tagged.
Location/Qualifiers
1..30
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/db_xref="taxon:3702"
/clone="SALK_149938.31.65.x"
/clone_lib="Arabidopsis thaliana TDNA insertion lines"
/note="PCR was performed on Arabidopsis thaliana lines
each of which contains one or more TDNA insertion
elements. The resultant fragment for each line was
directly sequenced to determine the genomic sequence at
the site of insertion. Details of the protocols used can
be found at http://signal.salk.edu/tdna_protocols.html"
ORIGIN
Query Match      53.3%; Score 11.2; DB 9; Length 30;
Best Local Similarity 68.8%; Pred. No. 6.8e+05;
Matches 11; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy      1 CUGAGUUUAAAAGGCA 16
        ||||| :|||||
Db      2 CGGAGTATATAAGGAA 17

RESULT 6
AZ804304/c
LOCUS     AZ804304 30 bp DNA linear GSS 16-FEB-2001
DEFINITION 2M0065M14F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
            clone UUGC2M0065M14 F, genomic survey sequence.
ACCESSION AZ804304
VERSION   AZ804304.1 GI:12956627
KEYWORDS  GSS.
SOURCE    Mus musculus (house mouse)
ORGANISM  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
            Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
            1 (bases 1 to 30)
            Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamill,C.,
            Ielam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
            Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
            Niederhausern,A. and Wright,D., Weiss,R.
            Mouse whole genome scaffolding with paired end reads from 10kb
            plasmid inserts
            Unpublished (2000)
            Contact: Robert B. Weiss
            University of Utah Genome Center
            University of Utah
            Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
            84112, USA
            Tel: 801 585 5606
            Fax: 801 585 7177
            Email: ddunn@genetics.utah.edu
            Insert Length: 10000 Std Error: 0.00
            Plate: 0065 row: M column: 14
            Seq primer: CGTTGTAATAACGACGCCAGT
            Class: plasmid ends
            High quality sequence stop: 30.
FEATURES
source      Location/Qualifiers
              1..30
              /organism="Mus musculus"
              /mol_type="genomic DNA"
              /strain="C57BL/6J"
              /db_xref="taxon:10090"
              /clone="UUGC2M0065M14"
              /sex="Male"
              /lab_host="E. Coli strain XL10-Gold, Tl-resistant, F-"
              /clone_lib="Mouse 10kb plasmid UUGC1M library"
              /note="Vector: pWD42nv; Purified genomic DNA from M.
              musculus C57BL/6J (male) was obtained from the Jackson
              Laboratory Mouse DNA Resource

```

(<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pW42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

ORIGIN

Query Match 51.4%; Score 10.8; DB 8; Length 30;
 Best Local Similarity 64.3%; Pred. No. 1.1e+06;
 Matches 9; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

Qy 2 UGAGUUUAAAGGC 15
 :|||: : |||||
 Db 28 TGAGTCTCAAAGGC 15

RESULT 7

AZ864535/c
 LOCUS 20174J12F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 DEFINITION clone UUGC2M0174J12 F, genomic survey sequence.

ACCESSION AZ864535
 VERSION 1
 KEYWORDS GI:130633933
 SOURCE GSS.

Mus musculus (house mouse)

ORGANISM

Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

AUTHORS 1 (bases 1 to 20)
 Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
 Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
 Reilly,M., Rose,R., Stokes,R., Tingey,A., von
 Niederhausern,A. and Wright,D.,Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts

JOURNAL

COMMENT Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0174 row: J column: 12

Seq primer: CGTTGTAAACGACGGCCAGT

Class: plasmid ends

High quality sequence stop: 20.

Location/Qualifiers

FEATURES
 source

1. .20
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC2M0174J12"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /note="vector: PWD42nv; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource

(<http://www.jax.org/resources/documents/dnares/>). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adapted DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pW42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adapted mouse DNA was annealed to adapted vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

ORIGIN

Query Match 50.5%; Score 10.6; DB 8; Length 20;
 Best Local Similarity 64.7%; Pred. No. 1.3e+06;
 Matches 11; Conservative 2; Mismatches 4; Indels 0; Gaps 0;

Qy 3 GAGUUUAAAGGCACCC 19
 |::: ||||| |||
 Db 20 GTGTTGATAGGCCCCC 4

RESULT 8

AZ397442/c
 LOCUS 1M0162K19F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
 DEFINITION clone UUGC1M0162K19 F, genomic survey sequence.

ACCESSION AZ397442
 VERSION 1
 KEYWORDS GI:10512514
 SOURCE GSS.

Mus musculus (house mouse)

ORGANISM

Mus musculus
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

AUTHORS 1 (bases 1 to 25)
 Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
 Islam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
 Reilly,M., Rose,R., Stokes,R., Tingey,A., von
 Niederhausern,A. and Wright,D.,Weiss,R.

TITLE Mouse whole genome scaffolding with paired end reads from 10kb
 plasmid inserts

JOURNAL

COMMENT Unpublished (2000)
 Contact: Robert B. Weiss
 University of Utah Genome Center
 University of Utah
 Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
 84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0162 row: K column: 19

Seq primer: CGTTGTAAACGACGGCCAGT

Class: plasmid ends

High quality sequence stop: 25.

Location/Qualifiers

FEATURES
 source

1. .25
 /organism="Mus musculus"
 /mol_type="genomic DNA"
 /strain="C57BL/6J"
 /db_xref="taxon:10090"
 /clone="UUGC1M0162K19"
 /sex="Male"
 /lab_host="E. Coli strain XL10-Gold, T1-resistant, F-"
 /clone_lib="Mouse 10kb plasmid UUGC1M library"
 /note="vector: PWD42nv; Purified genomic DNA from M.
 musculus C57BL/6J (male) was obtained from the Jackson
 Laboratory Mouse DNA Resource


```
/db_xref=taxon:10090"
/clones="UUGC1M0538F04"
/lab host="E. Coli strain XL10-Gold, T1-resistant, F-"
/sex="Male"
/clone lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: pMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
```

ORIGIN

```
Query Match 49.5%; Score 10.4; DB 8; Length 24;
Best Local Similarity 58.3%; Pred. No. 1.7e+06;
Matches 7; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2 UGAGUUUAAAG 13
Db 22 TGTGTTTAAAG 11
```

```
RESULT 14
A2457829/c
LOCUS
DEFINITION A2457829 Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0261C20 F, genomic survey sequence.
ACCESSION A2457829
VERSION A2457829.1 GI:10615954
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 29)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Irlam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0261 row: C column: 20
Seq primer: CGTTGTAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 29.
```

```
FEATURES
source
1. 29
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
```

```
/db_xref=taxon:10090"
/clones="UUGC1M0261C20"
/lab host="E. Coli strain XL10-Gold, T1-resistant, F-"
/sex="Male"
/clone lib="Mouse 10kb plasmid UUGC1M library"
/notes="Vector: pMD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of pMD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."
```

ORIGIN

```
Query Match 49.5%; Score 10.4; DB 8; Length 29;
Best Local Similarity 58.3%; Pred. No. 1.7e+06;
Matches 7; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
```

```
Qy 2 UGAGUUUAAAG 13
Db 20 TCAGTTTAAAG 9
```

```
RESULT 15
A2813693
LOCUS
DEFINITION A2813693 Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC2M0081P03 F, genomic survey sequence.
ACCESSION A2813693
VERSION A2813693.1 GI:12983601
KEYWORDS GSS.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 29)
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,
Irlam,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,
Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von
Niederhausern,A. and Wright,D., Weiss,R.
Mouse whole genome scaffolding with paired end reads from 10kb
plasmid inserts
Unpublished (2000)
Contact: Robert B. Weiss
University of Utah Genome Center
Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT
84112, USA
Tel: 801 585 5606
Fax: 801 585 7177
Email: ddunn@genetics.utah.edu
Insert Length: 10000 Std Error: 0.00
Plate: 0081 row: P column: 03
Seq primer: CGTTGTAACGACGCCAGT
Class: plasmid ends
High quality sequence stop: 29.
```

```
FEATURES
source
1. 29
/organism="Mus musculus"
/mol_type="genomic DNA"
/strain="C57BL/6J"
```

```

/db xref="taxon:10090"
/clone="UUGC2M0081P03"
/sex="Male"
/lab host="E. Coli strain XL10-Gold, T1-resistant, F-"
/clone_lib="Mouse 10kb plasmid UUGC1M library"
/note="vector: PWD42nv; Purified genomic DNA from M. musculus C57BL/6J (male) was obtained from the Jackson Laboratory Mouse DNA Resource (http://www.jax.org/resources/documents/dnares/). The DNA was hydrodynamically sheared by repeated passage through a 0.005 inch orifice at constant velocity. The sheared DNA was blunt end-repaired with T4 DNA polymerase and T4 polynucleotide kinase. Adaptor oligonucleotides were ligated to the blunt ends in high molar excess. The adaptor DNA was purified and size-selected for a 9.5 to 10.5 kb range using preparative agarose gel electrophoresis. Vector DNA was prepared from a derivative of PWD42 (gi|4732114|gb|AF129072.1), a copy-number inducible derivative of plasmid R1. The vector was ligated with adaptors complementary to the insert adaptors and purified. The sheared, adaptor mouse DNA was annealed to adaptor vector DNA, and transformed into chemically-competent E. coli XL10-Gold (Stratagene) cells and selected for ampicillin resistance."

```

ORIGIN

```

Query Match      49.5%; Score 10.4; DB 8; Length 29;
Best Local Similarity 58.3%; Pred. No. 1.7e+06;
Matches 7; Conservative 4; Mismatches 1; Indels 0; Gaps 0;

QY      1 CUGAGUUUUAAA 12
        |:|:|:|:|:|
Db       12 CTGACTTTAAAA 23

```

Search completed: August 19, 2005, 01:37:26
Job time : 2980 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2005 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 18, 2005, 22:25:38 ; Search time 416 Seconds
(without alignments)
298.833 Million cell updates/sec

Title: US-10-665-951-2185
Perfect score: 21
Sequence: 1 cugaguuaaaagcaccm 21

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 4390206 seqs, 2959870667 residues

Total number of hits satisfying chosen parameters: 3522762

Minimum DB seq length: 0

Maximum DB seq length: 30

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N Geneseq_16Dec04.*
1: Geneseq_1980s.*
2: Geneseq_1990s.*
3: Geneseq_2000s.*
4: Geneseq_2001as.*
5: Geneseq_2001bs.*
6: Geneseq_2002as.*
7: Geneseq_2002bs.*
8: Geneseq_2003as.*
9: Geneseq_2003bs.*
10: Geneseq_2003cs.*
11: Geneseq_2003ds.*
12: Geneseq_2004as.*
13: Geneseq_2004bs.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	19	90.5	21	9 ADA13968	ADA13968 Short int
C 2	19	90.5	21	9 ADA13964	ADA13964 Short int
C 3	19	90.5	21	9 ADA13613	ADA13613 Short int
C 4	19	90.5	21	9 ADA13960	ADA13960 Short int
C 5	19	90.5	21	10 ADF37903	Adf37903 Human VEG
C 6	19	90.5	21	10 ADF37751	Adf37751 Human VEG
C 7	19	90.5	21	10 ADF37745	Adf37745 Human VEG
C 8	19	90.5	21	10 ADF37775	Adf37775 Human VEG
C 9	19	90.5	21	10 ADF37899	Adf37899 Human VEG
C 10	19	90.5	21	10 ADF37907	Adf37907 Human VEG
C 11	19	90.5	21	10 ADF37736	Adf37736 Human VEG
C 12	19	90.5	21	10 ADF37895	Adf37895 Human VEG
C 13	19	90.5	21	10 ADF37739	Adf37739 Human VEG
C 14	19	90.5	21	10 ADF39836	Adg29836 FLT1-targ
C 15	19	90.5	21	10 ADG29884	Adg29884 FLT1-targ
C 16	19	90.5	21	10 ADG29890	Adg29890 FLT1-targ
C 17	19	90.5	21	10 ADG29832	Adg29832 FLT1-targ
C 18	19	90.5	21	10 ADG29896	Adg29896 FLT1-targ
C 19	19	90.5	21	10 ADG29828	Adg29828 FLT1-targ
C 20	19	90.5	21	10 ADG29881	Adg29881 FLT1-targ

C 21	19	90.5	21	10 ADG29920	Adg29920 FLT1-targ
C 22	19	90.5	21	10 ADG29824	Adg29824 FLT1-targ
C 23	19	90.5	23	10 ADF37772	Adf37772 Human VEG
C 24	19	90.5	23	10 ADF37812	Adf37812 Human VEG
C 25	19	90.5	23	10 ADF37742	Adf37742 Human VEG
C 26	19	90.5	23	10 ADF37748	Adf37748 Human VEG
C 27	19	90.5	23	10 ADG29490	Adg29490 FLT1-targ
C 28	19	90.5	23	10 ADG29893	Adg29893 FLT1-targ
C 29	19	90.5	23	10 ADG29917	Adg29917 FLT1-targ
C 30	19	90.5	23	10 ADG29887	Adg29887 FLT1-targ
C 31	17	81.0	17	2 AAX74493	Aax74493 Mouse flt
C 32	17	81.0	17	2 AAX68744	Aax68744 Human flt
C 33	17	81.0	20	8 ACC86729	Acc86729 Human VEG
C 34	16	76.2	17	2 AAX68743	Aax68743 Human flt
C 35	16	76.2	17	2 AAX74492	Aax74492 Mouse flt
C 36	16	76.2	20	8 ACC86730	Acc86730 Human VEG
C 37	15	71.4	17	2 AAX68742	Aax68742 Human flt
C 38	15	71.4	17	2 AAX74491	Aax74491 Mouse flt
C 39	14.2	67.6	22	3 AAZ87380	Aaz87380 Human thr
C 40	14.2	67.6	24	3 AAZ87381	Aaz87381 Human thr
C 41	13.8	65.7	28	2 AAX28169	Aax28169 PCR prime
C 42	13.2	62.9	30	2 AAT58464	Aat58464 PEPCK gen
C 43	13.2	62.9	30	2 AAV82574	Av82574 PCR prime
C 44	13	61.9	19	10 ADF35731	Adf35731 Human VEG
C 45	13	61.9	19	10 ADF36158	Adf36158 Human VEG

ALIGNMENTS

RESULT 1
ADA13968/c
ID ADA13968 standard; RNA; 21 BP.
XX
AC ADA13968;
DT 20-NOV-2003 (first entry)
XX Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:305.
DE
XX double-stranded short interfering nucleic acid;
XX short interfering nucleic acid; siNA; expression; replication;
KW inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
KW antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
KW cytosolic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
KW endocrine; viral infection; hepatitis B; hepatitis C; HIV;
KW herpes simplex; cytomegalovirus; human papillomavirus;
KW respiratory syncytial virus; influenza virus; restenosis;
KW neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
KW pulmonary; renal; liver; mitochondrial; reproductive disease;
KW chemical modification; ss.
XX Synthetic.
OS
XX WO2003070918-A2.
PN
XX 28-AUG-2003.
PD
XX 20-FEB-2003; 2003WO-US005346.
PF
XX 20-FEB-2002; 2002US-0358580P.
PR
XX 11-MAR-2002; 2002US-0363124P.
PR
XX 06-JUN-2002; 2002US-0386782P.
PR
XX 29-AUG-2002; 2002US-0406784P.
PR
XX 05-SEP-2002; 2002US-0408378P.
PR
XX 09-SEP-2002; 2002US-0409293P.
PR
XX 15-JAN-2003; 2003US-0440129P.
XX (RIBO-) RIBOZYME PHARM INC.
XX Mcswiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
XX Morrissey D, Fomenaugh K, Mokler V, Jamison S;

```
DR WPI; 2003-689785/65.
XX
XX New short interfering nucleic acid containing no ribonucleotides, useful
PT e.g. for treating viral infection, downregulates expression of target
PT gene or RNA.
XX
XX Example 4; Page 142; 204pp; English.
XX
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of a target gene, where
CC the siNA molecule comprises no ribonucleotides and each strand of the
CC double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC molecule that inhibits replication of a virus and optionally does not
CC require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC that improves expression of a target gene and does not require presence
CC of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC expression of a target gene by mediating RNA interference; and (5) a
CC method for modulating expression of a gene in a cell using siNA
CC molecules. siNA's can have virucide, anti-HIV, hepatotropic,
CC antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC cytosstatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC and endocrine activities. The siNA's are useful for downregulating
CC expression of target genes, inhibiting expression of target RNA, and
CC inhibiting replication of a virus. siNA molecules can be used: (a) for
CC therapy of any disorder that responds to modulation of gene expression,
CC especially animal and plant viral infections, specifically hepatitis B or
CC C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory
CC syncytial or influenza viruses, and also many other diseases such as
CC restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC endocrine or reproductive diseases; and (b) for diagnosis, target
CC validation, genomic discovery, genetic engineering, pharmacogenomics and
CC analysis of gene function. Chemical modification of siNA molecules
CC improves interfering activity; stability; cellular uptake; binding
CC affinity and/or mediates increased polymerase activity. siNA may be
CC designed to target many related genes containing a conserved sequence.
CC The present sequence represents a siNA oligonucleotide sequence, which is
CC used in the exemplification of the present invention.
XX
XX Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;
XX
XX Query Match 90.5%; Score 19; DB 9; Length 21;
XX Best Local Similarity 78.9%; Pred. No. 1.8;
XX Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 CUGAGUUUAAAAGGCACCC 19
XX 19 CTGAGTTTAAAGGCACCC 1
XX
XX RESULT 2
XX ADA13964/c
XX ID ADA13964 standard; RNA; 21 BP.
XX
XX AC ADA13964;
XX
XX 20-NOV-2003 (first entry)
XX
XX Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:301.
XX
XX double-stranded short interfering nucleic acid;
XX short interfering nucleic acid; siNA; expression; replication;
XX inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
XX antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
XX cytosstatic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
XX endocrine; viral infection; hepatitis B; hepatitis C; HIV;
XX herpes simplex; cytomegalovirus; human papillomavirus;
XX respiratory syncytial virus; influenza virus; restenosis;
XX neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
XX pulmonary; renal; liver; mitochondrial; reproductive disease;
XX chemical modification; ss.
XX
```

```
OS Synthetic.
XX
XX W02003070918-A2.
XX
XX 28-AUG-2003.
XX
XX 20-FEB-2003; 2003WO-US005346.
XX
XX 20-FEB-2002; 2002US-0358580P.
XX 11-MAR-2002; 2002US-0363124P.
XX 06-JUN-2002; 2002US-0386782P.
XX 29-AUG-2002; 2002US-0406784P.
XX 05-SEP-2002; 2002US-0408378P.
XX 09-SEP-2002; 2002US-0409293P.
XX 15-JAN-2003; 2003US-0440129P.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX McSwiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
XX Morrissey D, Fosnaugh K, Mokler V, Jamison S;
XX
XX WPI; 2003-689785/65.
XX
XX New short interfering nucleic acid containing no ribonucleotides, useful
PT e.g. for treating viral infection, downregulates expression of target
PT gene or RNA.
XX
XX Example 4; Page 142; 204pp; English.
XX
XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of a target gene, where
CC the siNA molecule comprises no ribonucleotides and each strand of the
CC double-stranded siNA comprises about 21 nucleotides. Also described: (1)
CC a siNA molecule that inhibits expression of target RNA; (2) a siNA
CC molecule that inhibits replication of a virus and optionally does not
CC require presence of a ribonucleotide for inhibition; (3) a siNA molecule
CC that improves expression of a target gene and does not require presence
CC of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
CC expression of a target gene by mediating RNA interference; and (5) a
CC method for modulating expression of a gene in a cell using siNA
CC molecules. siNA's can have virucide, anti-HIV, hepatotropic,
CC antiinflammatory, plant antiviral, vasotropic, neuroprotective,
CC cytosstatic, cardiovascular, immunosuppressive, respiratory, nephrotropic
CC and endocrine activities. The siNA's are useful for downregulating
CC expression of target genes, inhibiting expression of target RNA, and
CC inhibiting replication of a virus. siNA molecules can be used: (a) for
CC therapy of any disorder that responds to modulation of gene expression,
CC especially animal and plant viral infections, specifically hepatitis B or
CC C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory
CC syncytial or influenza viruses, and also many other diseases such as
CC restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
CC prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,
CC endocrine or reproductive diseases; and (b) for diagnosis, target
CC validation, genomic discovery, genetic engineering, pharmacogenomics and
CC analysis of gene function. Chemical modification of siNA molecules
CC improves interfering activity; stability; cellular uptake; binding
CC affinity and/or mediates increased polymerase activity. siNA may be
CC designed to target many related genes containing a conserved sequence.
CC The present sequence represents a siNA oligonucleotide sequence, which is
CC used in the exemplification of the present invention.
XX
XX Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;
XX
XX Query Match 90.5%; Score 19; DB 9; Length 21;
XX Best Local Similarity 78.9%; Pred. No. 1.8;
XX Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
XX
XX 1 CUGAGUUUAAAAGGCACCC 19
XX 19 CTGAGTTTAAAGGCACCC 1
XX
XX RESULT 3
```

ADA13613
 ID ADA13613 standard; RNA; 21 BP.
 XX
 AC ADA13613;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:345.
 XX
 KW double-stranded short interfering nucleic acid;
 KW short interfering nucleic acid; siNA; expression; replication;
 KW inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
 KW antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
 KW cytosolic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
 KW endocrine; viral infection; hepatitis B; hepatitis C; HIV;
 KW herpes simplex; cytomegalovirus; human papillomavirus;
 KW respiratory syncytial virus; influenza virus; restenosis;
 KW neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
 KW pulmonary; renal; liver; mitochondrial; reproductive disease;
 KW chemical modification; ss.
 XX
 OS Synthetic.
 XX
 XX WO2003070918-A2.
 XX
 XX 28-AUG-2003.
 XX
 XX 20-FEB-2003; 2003WO-US005346.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 XX 11-MAR-2002; 2002US-0363124P.
 XX 06-JUN-2002; 2002US-0386782P.
 XX 29-AUG-2002; 2002US-0406784P.
 XX 05-SEP-2002; 2002US-0408378P.
 XX 09-SEP-2002; 2002US-0409293P.
 XX 15-JAN-2003; 2003US-0440129P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Mcswiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
 XX Morrissey D, Fossnaugh K, Mokler V, Jamison S;
 XX WPI; 2003-689785/65.
 XX
 XX New short interfering nucleic acid containing no ribonucleotides, useful
 XX e.g. for treating viral infection, downregulates expression of target
 XX gene or RNA.
 XX
 XX Example 4; Page 144; 204pp; English.
 XX
 XX The present invention describes a double-stranded short interfering
 XX nucleic acid (siNA) that downregulates expression of a target gene, where
 XX the siNA molecule comprises no ribonucleotides and each strand of the
 XX double-stranded siNA comprises about 21 nucleotides. Also described: (1)
 XX a siNA molecule that inhibits expression of target RNA; (2) a siNA
 XX molecule that inhibits replication of a virus and optionally does not
 XX require presence of a ribonucleotide for inhibition; (3) a siNA molecule
 XX that inhibits expression of a target gene and does not require presence
 XX of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
 XX expression of a target gene by mediating RNA interference; and (5) a
 XX method for modulating expression of a gene in a cell using siNA
 XX molecules. siNA's can have virucide, anti-HIV, hepatotropic,
 XX antiinflammatory, plant antiviral, vasotropic, neuroprotective,
 XX cytosolic, cardiovascular, immunosuppressive, respiratory, nephrotropic
 XX and endocrine activities. The siNA's are useful for downregulating
 XX expression of target genes, inhibiting expression of target RNA, and
 XX inhibiting replication of a virus. siNA molecules can be used: (a) for
 XX therapy of any disorder that responds to modulation of gene expression,
 XX especially animal and plant viral infections, specifically hepatitis B or
 XX C; HIV; herpes simplex; cytomegalovirus; human papilloma; respiratory
 XX syncytial or influenza viruses, and also many other diseases such as
 XX restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
 XX prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,

CC endocrine or reproductive diseases; and (b) for diagnosis, target
 CC validation, genomic discovery, genetic engineering, pharmacogenomics and
 CC analysis of gene function. Chemical modification of siNA molecules
 CC improves interfering activity; stability; cellular uptake; binding
 CC affinity and/or mediates increased polymerase activity. siNA may be
 CC designed to target many related genes containing a conserved sequence.
 CC The present sequence represents a siNA oligonucleotide sequence, which is
 CC used in the exemplification of the present invention.
 XX
 XX Sequence 21 BP; 6 A; 5 C; 4 G; 2 T; 4 U; 0 Other;
 XX
 XX Query Match 90.5%; Score 19; DB 9; Length 21;
 XX Best Local Similarity 100.0%; Pred. No. 1.8;
 XX Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX
 Qy 1 CUGAGUUUUUUAAAGGCACCC 19
 Db 1 CUGAGUUUUUUAAAGGCACCC 19
 XX
 RESULT 4
 ADA13960
 ID ADA13960 standard; RNA; 21 BP.
 XX
 AC ADA13960;
 XX
 DT 20-NOV-2003 (first entry)
 XX
 DE Short interfering nucleic acid (siNA) oligonucleotide SEQ ID NO:297.
 XX
 KW double-stranded short interfering nucleic acid;
 KW short interfering nucleic acid; siNA; expression; replication;
 KW inhibition; RNA interference; virucide; anti-HIV; hepatotropic;
 KW antiinflammatory; plant; antiviral; vasotropic; neuroprotective;
 KW cytosolic; cardiovascular; immunosuppressive; respiratory; nephrotropic;
 KW endocrine; viral infection; hepatitis B; hepatitis C; HIV;
 KW herpes simplex; cytomegalovirus; human papillomavirus;
 KW respiratory syncytial virus; influenza virus; restenosis;
 KW neurodegeneration; cancer; neurological; prion; inflammatory; autoimmune;
 KW pulmonary; renal; liver; mitochondrial; reproductive disease;
 KW chemical modification; ss.
 XX
 OS Synthetic.
 XX
 XX WO2003070918-A2.
 XX
 XX 28-AUG-2003.
 XX
 XX 20-FEB-2003; 2003WO-US005346.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 XX 11-MAR-2002; 2002US-0363124P.
 XX 06-JUN-2002; 2002US-0386782P.
 XX 29-AUG-2002; 2002US-0406784P.
 XX 05-SEP-2002; 2002US-0408378P.
 XX 09-SEP-2002; 2002US-0409293P.
 XX 15-JAN-2003; 2003US-0440129P.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Mcswiggen J, Beigelman L, Macejak D, Zinnen S, Pavco P;
 XX Morrissey D, Fossnaugh K, Mokler V, Jamison S;
 XX WPI; 2003-689785/65.
 XX
 XX New short interfering nucleic acid containing no ribonucleotides, useful
 XX e.g. for treating viral infection, downregulates expression of target
 XX gene or RNA.
 XX
 XX Example 4; Page 144; 204pp; English.
 XX
 XX The present invention describes a double-stranded short interfering
 XX nucleic acid (siNA) that downregulates expression of a target gene, where
 XX the siNA molecule comprises no ribonucleotides and each strand of the
 XX double-stranded siNA comprises about 21 nucleotides. Also described: (1)
 XX a siNA molecule that inhibits expression of target RNA; (2) a siNA
 XX molecule that inhibits replication of a virus and optionally does not
 XX require presence of a ribonucleotide for inhibition; (3) a siNA molecule
 XX that inhibits expression of a target gene and does not require presence
 XX of a ribonucleotide for inhibition; (4) a siNA molecule that inhibits
 XX expression of a target gene by mediating RNA interference; and (5) a
 XX method for modulating expression of a gene in a cell using siNA
 XX molecules. siNA's can have virucide, anti-HIV, hepatotropic,
 XX antiinflammatory, plant antiviral, vasotropic, neuroprotective,
 XX cytosolic, cardiovascular, immunosuppressive, respiratory, nephrotropic
 XX and endocrine activities. The siNA's are useful for downregulating
 XX expression of target genes, inhibiting expression of target RNA, and
 XX inhibiting replication of a virus. siNA molecules can be used: (a) for
 XX therapy of any disorder that responds to modulation of gene expression,
 XX especially animal and plant viral infections, specifically hepatitis B or
 XX C; HIV; herpes simplex; cytomegalovirus; human papilloma; respiratory
 XX syncytial or influenza viruses, and also many other diseases such as
 XX restenosis, neurodegeneration, cancers, and cardiovascular, neurological,
 XX prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial,

the siRNA molecule comprises no ribonucleotides and each strand of the double-stranded siRNA comprises about 21 nucleotides. Also described: (1) a siRNA molecule that inhibits expression of target RNA; (2) a siRNA molecule that inhibits replication of a virus and optionally does not require presence of a ribonucleotide for inhibition; (3) a siRNA molecule that inhibits expression of a target gene and does not require presence of a ribonucleotide for inhibition; (4) a siRNA molecule that inhibits expression of a target gene by mediating RNA interference; and (5) a method for modulating expression of a gene in a cell using siRNA molecules. siRNA's can have virucide, anti-HIV, hepatotropic, antiinflammatory, plant antiviral, vasotropic, neuroprotective, cytostatic, cardiovascular, immunosuppressive, respiratory, nephrotropic and endocrine activities. The siRNA's are useful for downregulating expression of target genes, inhibiting expression of target RNA, and inhibiting replication of a virus. siRNA molecules can be used: (a) for therapy of any disorder that responds to modulation of gene expression, especially animal and plant viral infections, specifically hepatitis B or C; HIV; herpes simplex; cytomegalo; human papilloma; respiratory syncytial or influenza viruses, and also many other diseases such as restenosis, neurodegeneration, cancers, and cardiovascular, neurological, prion, inflammatory, autoimmune, pulmonary, renal, liver, mitochondrial, endocrine or reproductive diseases; and (b) for diagnosis, target validation, genomic discovery, genetic engineering, pharmacogenomics and analysis of gene function. Chemical modification of siRNA molecules improves interfering activity; stability; cellular uptake; binding affinity and/or mediates increased polymerase activity. siRNA may be designed to target many related genes containing a conserved sequence. The present sequence represents a siRNA oligonucleotide sequence, which is used in the exemplification of the present invention.

XX Sequence 21 BP; 6 A; 5 C; 4 G; 2 T; 4 U; 0 Other;

SQ Query Match 90.5%; Score 19; DB 9; Length 21;

Best Local Similarity 100.0%; Pred. No. 1.8; Length 21;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19

Db 1 CUGAGUUUAAAAGGCACCC 19

RESULT 5

ADF37903 ID ADF37903 standard; RNA; 21 BP.

XX ADF37903;

XX 12-FEB-2004 (first entry)

XX Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2100.

XX double-stranded short interfering nucleic acid;
KW short interfering nucleic acid; siNA; downregulation;
KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
KW cytoskeletal; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
KW arthritis; psoriasis; endometriosis; angiofibroma;
KW polycystic kidney disease; ss.

XX Synthetic.

OS Homo sapiens.

XX WO2003070910-A2.

XX 28-AUG-2003.

XX 20-FEB-2003; 2003WO-US005022.

XX 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 29-MAY-2002; 2002WO-US017674.

PR 06-JUN-2002; 2002US-0386782P.

PR 03-JUL-2002; 2002US-0393796P.

PR 29-JUL-2002; 2002US-0399348P.

PR 29-AUG-2002; 2002US-0406784P.

PR 03-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 04-NOV-2002; 2002US-00287949.

PR 27-NOV-2002; 2002US-00306747.

PR 15-JAN-2003; 2003US-0440129P.

XX (RIBO-) RIBOZYME PHARM INC.

XX McSwiggen J, Beigelman L, Pavco P;

XX WPI; 2003-679876/64.

XX New double-stranded interfering nucleic acid, useful e.g. for treatment
PT and diagnosis of cancer, downregulates the vascular endothelial growth
PT factor receptor gene.

XX Example 3; SEQ ID NO 2100; 207pp; English.

XX The present invention describes a double-stranded short interfering
CC nucleic acid (siNA) that downregulates expression of the vascular
CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
CC that express siNA; and (5) single-stranded siNA with similar properties.
CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
CC gynaecological activities. The siNA are useful for modulating
CC (downregulating) the expression of VEGFR genes. The siNA are potentially
CC useful for treating a wide range of angiogenesis-associated conditions,
CC particularly cancers, diabetic retinopathy, macular degeneration,
CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
CC drug screening, target identification and validation, genetic
CC engineering, studying gene function, and also for gene mapping (e.g. of
CC single-nucleotide polymorphisms). The present sequence is used in the
CC exemplification of the present invention.

SQ Sequence 21 BP; 6 A; 5 C; 4 G; 2 T; 4 U; 0 Other;

Query Match 90.5%; Score 19; DB 10; Length 21;

Best Local Similarity 100.0%; Pred. No. 1.8;
Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19

Db 1 CUGAGUUUAAAAGGCACCC 19

RESULT 6

ADF37751/c

ID ADF37751 standard; RNA; 21 BP.

XX ADF37751;

XX 12-FEB-2004 (first entry)

XX Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2164.

XX double-stranded short interfering nucleic acid;

KW short interfering nucleic acid; siNA; downregulation;

KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;

KW cytoskeletal; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;

KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;

KW diabetic retinopathy; macular degeneration; neovascular glaucoma;

KW arthritis; psoriasis; endometriosis; angiofibroma;

KW polycystic kidney disease; ss.

XX Synthetic.

OS Homo sapiens.

XX

PN WO2003070910-A2.
 XX 28-AUG-2003.
 XX 20-FEB-2003; 2003WO-US005022.
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 29-MAY-2002; 2002WO-US017674.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 03-JUL-2002; 2002US-0393796P.
 PR 29-JUL-2002; 2002US-0399348P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 04-NOV-2002; 2002US-00287949.
 PR 27-NOV-2002; 2002US-00306747.
 PR 15-JAN-2003; 2003US-0440129P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Mcswiggen J, Beigelman L, Pavco P;
 PI WPI; 2003-679876/64.
 XX New double-stranded interfering nucleic acid, useful e.g. for treatment
 PT and diagnosis of cancer, downregulates the vascular endothelial growth
 PT factor receptor gene.
 XX Example 3; SEQ ID NO 2164; 207pp; English.
 XX The present invention describes a double-stranded short interfering
 CC nucleic acid (siNA) that downregulates expression of the vascular
 CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
 CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
 CC that express siNA; and (5) single-stranded siNA with similar properties.
 CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
 CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
 CC gynaecological activities. The siNA are useful for modulating
 CC (downregulating) the expression of VEGFR genes. The siNA are potentially
 CC useful for treating a wide range of angiogenesis-associated conditions,
 CC particularly cancers, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
 CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
 CC drug screening, target identification and validation, genetic
 CC engineering, studying gene function, and also for gene mapping (e.g. of
 CC single-nucleotide polymorphisms). The present sequence is used in the
 CC exemplification of the present invention.
 XX Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;
 SQ Query Match 90.5%; Score 19; DB 10; Length 21;
 Best Local Similarity 78.9%; Pred. No. 1.8;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 1 CUGAGUUUAAAAGGCACCC 19
 DB 19 CTGAGTTTAAAGGCACCC 1
 RESULT 7
 ADF37745/c
 ID ADF37745 standard; RNA; 21 BP.
 XX ADF37745;
 AC ADF37745;
 XX 12-FEB-2004 (first entry)
 DT Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2158.
 DE double-stranded short interfering nucleic acid;
 XX short interfering nucleic acid; siNA; downregulation;
 KW ADF37775/c
 XX Query Match 90.5%; Score 19; DB 10; Length 21;
 Best Local Similarity 78.9%; Pred. No. 1.8;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 1 CUGAGUUUAAAAGGCACCC 19
 DB 19 CTGAGTTTAAAGGCACCC 1
 RESULT 8
 ADF37775/c

KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
 KW cytostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
 KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
 KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
 KW arthritis; psoriasis; endometriosis; angiofibroma;
 KW polycystic kidney disease; ss.
 XX Synthetic.
 OS Homo sapiens.
 XX WO2003070910-A2.
 XX 28-AUG-2003.
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 29-MAY-2002; 2002WO-US017674.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 03-JUL-2002; 2002US-0393796P.
 PR 29-JUL-2002; 2002US-0399348P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 04-NOV-2002; 2002US-00287949.
 PR 27-NOV-2002; 2002US-00306747.
 PR 15-JAN-2003; 2003US-0440129P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA Mcswiggen J, Beigelman L, Pavco P;
 PI WPI; 2003-679876/64.
 XX New double-stranded interfering nucleic acid, useful e.g. for treatment
 PT and diagnosis of cancer, downregulates the vascular endothelial growth
 PT factor receptor gene.
 XX Example 3; SEQ ID NO 2158; 207pp; English.
 XX The present invention describes a double-stranded short interfering
 CC nucleic acid (siNA) that downregulates expression of the vascular
 CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
 CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
 CC that express siNA; and (5) single-stranded siNA with similar properties.
 CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
 CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
 CC gynaecological activities. The siNA are useful for modulating
 CC (downregulating) the expression of VEGFR genes. The siNA are potentially
 CC useful for treating a wide range of angiogenesis-associated conditions,
 CC particularly cancers, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
 CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
 CC drug screening, target identification and validation, genetic
 CC engineering, studying gene function, and also for gene mapping (e.g. of
 CC single-nucleotide polymorphisms). The present sequence is used in the
 CC exemplification of the present invention.
 XX Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;
 SQ Query Match 90.5%; Score 19; DB 10; Length 21;
 Best Local Similarity 78.9%; Pred. No. 1.8;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 1 CUGAGUUUAAAAGGCACCC 19
 DB 19 CTGAGTTTAAAGGCACCC 1

ID ADF37775 standard; RNA; 21 BP.
 AC ADF37775;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2188.
 XX
 XX double-stranded short interfering nucleic acid;
 KW short interfering nucleic acid; siNA; downregulation;
 KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
 KW cyostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
 KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
 KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
 KW arthritis; psoriasis; endometriosis; angiofibroma;
 KW polycystic kidney disease; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX WO2003070910-A2.
 XX
 XX 28-AUG-2003.
 XX
 XX 20-FEB-2003; 2003WO-US005022.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 29-MAY-2002; 2002WO-US017674.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 03-JUL-2002; 2002US-0393796P.
 PR 29-JUL-2002; 2002US-0399348P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 04-NOV-2002; 2002US-00287949.
 PR 27-NOV-2002; 2002US-00306747.
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswiggen J, Beigelman L, Pavco P;
 XX
 XX WPI; 2003-679876/64.
 DR
 XX
 PT New double-stranded interfering nucleic acid, useful e.g. for treatment
 PT and diagnosis of cancer, downregulates the vascular endothelial growth
 PT factor receptor gene.
 XX
 XX Example 3; SEQ ID NO 2188; 207pp; English.
 XX
 CC The present invention describes a double-stranded short interfering
 CC nucleic acid (siNA) that downregulates expression of the vascular
 CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
 CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
 CC that express siNA; and (5) single-stranded siNA with similar properties.
 CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
 CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
 CC gynaecological activities. The siNA are useful for modulating
 CC (downregulating) the expression of VEGFR genes. The siNA are potentially
 CC useful for treating a wide range of angiogenesis-associated conditions,
 CC particularly cancers, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
 CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
 CC drug screening, target identification and validation, genetic
 CC engineering, studying gene function, and also for gene mapping (e.g. of
 CC single-nucleotide polymorphisms). The present sequence is used in the
 CC exemplification of the present invention.
 XX
 SQ Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;
 Query Match 90.5%; Score 19; DB 10; Length 21;

Best Local Similarity 78.9%; Pred. No. 1.8;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
 QY 1 CUGAGUUUUAAAAGCACCC 19
 DB 19 CTGAGTTTAAAGGCACCC 1
 RESULT 9
 ADF37899/c
 ID ADF37899 standard; RNA; 21 BP.
 XX
 AC ADF37899;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2096.
 XX
 XX double-stranded short interfering nucleic acid;
 KW short interfering nucleic acid; siNA; downregulation;
 KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
 KW cyostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
 KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
 KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
 KW arthritis; psoriasis; endometriosis; angiofibroma;
 KW polycystic kidney disease; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 XX WO2003070910-A2.
 XX
 XX 28-AUG-2003.
 XX
 XX 20-FEB-2003; 2003WO-US005022.
 XX
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 29-MAY-2002; 2002WO-US017674.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 03-JUL-2002; 2002US-0393796P.
 PR 29-JUL-2002; 2002US-0399348P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 04-NOV-2002; 2002US-00287949.
 PR 27-NOV-2002; 2002US-00306747.
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswiggen J, Beigelman L, Pavco P;
 XX
 XX WPI; 2003-679876/64.
 DR
 XX
 PT New double-stranded interfering nucleic acid, useful e.g. for treatment
 PT and diagnosis of cancer, downregulates the vascular endothelial growth
 PT factor receptor gene.
 XX
 XX Example 3; SEQ ID NO 2096; 207pp; English.
 XX
 CC The present invention describes a double-stranded short interfering
 CC nucleic acid (siNA) that downregulates expression of the vascular
 CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
 CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
 CC that express siNA; and (5) single-stranded siNA with similar properties.
 CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
 CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
 CC gynaecological activities. The siNA are useful for modulating
 CC (downregulating) the expression of VEGFR genes. The siNA are potentially
 CC useful for treating a wide range of angiogenesis-associated conditions,
 CC particularly cancers, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
 CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
 CC drug screening, target identification and validation, genetic
 CC engineering, studying gene function, and also for gene mapping (e.g. of
 CC single-nucleotide polymorphisms). The present sequence is used in the
 CC exemplification of the present invention.
 XX
 SQ Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;
 Query Match 90.5%; Score 19; DB 10; Length 21;

CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
 CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
 CC drug screening, target identification and validation, genetic
 CC engineering, studying gene function, and also for gene mapping (e.g. of
 CC single-nucleotide polymorphisms). The present sequence is used in the
 CC exemplification of the present invention.

XX Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

Query Match 90.5%; Score 19; DB 10; Length 21;

Best Local Similarity 78.9%; Pred. No. 1.8;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19

Db 19 CTGAGTTTAAAAGGCACCC 1

RESULT 10

ADF37907/C

ID ADF37907 standard; RNA; 21 BP.

XX ADF37907;

XX 12-FEB-2004 (first entry)

XX Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2104.

XX double-stranded short interfering nucleic acid;
 KW short interfering nucleic acid; siNA; downregulation;
 KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
 KW cytosstatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
 KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
 KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
 KW arthritis; psoriasis; endometriosis; angiofibroma;
 KW polycystic kidney disease; ss.

XX Synthetic.

OS Homo sapiens.

XX WO2003070910-A2.

XX 28-AUG-2003.

XX 20-FEB-2003; 2003WO-US005022.

XX 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 29-MAY-2002; 2002WO-US017674.

PR 06-JUN-2002; 2002US-0386782P.

PR 03-JUL-2002; 2002US-0393796P.

PR 29-JUL-2002; 2002US-0399348P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 04-NOV-2002; 2002US-00287949.

PR 27-NOV-2002; 2002US-00306747.

PR 15-JAN-2003; 2003US-0440129P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Mcswiggen J, Beigelman L, Pavco P;

XX WPI; 2003-679876/64.

XX New double-stranded interfering nucleic acid, useful e.g. for treatment
 PT and diagnosis of cancer, downregulates the vascular endothelial growth
 PT factor receptor gene.

XX Example 3; SEQ ID NO 2104; 207pp; English.

CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
 CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
 CC that express siNA; and (5) single-stranded siNA with similar properties.
 CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
 CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
 CC gynaecological activities. The siNA are useful for modulating
 CC (downregulating) the expression of VEGFR genes. The siNA are potentially
 CC useful for treating a wide range of angiogenesis-associated conditions,
 CC particularly cancers, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
 CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
 CC drug screening, target identification and validation, genetic
 CC engineering, studying gene function, and also for gene mapping (e.g. of
 CC single-nucleotide polymorphisms). The present sequence is used in the
 CC exemplification of the present invention.

XX Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

Query Match 90.5%; Score 19; DB 10; Length 21;

Best Local Similarity 78.9%; Pred. No. 1.8;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCACCC 19

Db 19 CTGAGTTTAAAAGGCACCC 1

RESULT 11

ADF37736

ID ADF37736 standard; RNA; 21 BP.

XX ADF37736;

XX 12-FEB-2004 (first entry)

XX Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2149.

XX double-stranded short interfering nucleic acid;
 KW short interfering nucleic acid; siNA; downregulation;
 KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
 KW cytosstatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
 KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
 KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
 KW arthritis; psoriasis; endometriosis; angiofibroma;
 KW polycystic kidney disease; ss.

XX Synthetic.

OS Homo sapiens.

XX WO2003070910-A2.

XX 28-AUG-2003.

XX 20-FEB-2003; 2003WO-US005022.

XX 20-FEB-2002; 2002US-0358580P.

PR 11-MAR-2002; 2002US-0363124P.

PR 29-MAY-2002; 2002WO-US017674.

PR 06-JUN-2002; 2002US-0386782P.

PR 03-JUL-2002; 2002US-0393796P.

PR 29-JUL-2002; 2002US-0399348P.

PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.

PR 09-SEP-2002; 2002US-0409293P.

PR 04-NOV-2002; 2002US-00287949.

PR 27-NOV-2002; 2002US-00306747.

PR 15-JAN-2003; 2003US-0440129P.

XX (RIBO-) RIBOZYME PHARM INC.

XX Mcswiggen J, Beigelman L, Pavco P;

DR WPI; 2003-679876/64.
 XX New double-stranded interfering nucleic acid, useful e.g. for treatment
 PT and diagnosis of cancer, downregulates the vascular endothelial growth
 PT factor receptor gene.
 XX
 PS Example 3; SEQ ID NO 2149; 207pp; English.
 XX
 CC The present invention describes a double-stranded short interfering
 CC nucleic acid (siNA) that downregulates expression of the vascular
 CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
 CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
 CC that express siNA; and (5) single-stranded siNA with similar properties.
 CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
 CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
 CC gynaecological activities. The siNA are useful for modulating
 CC (downregulating) the expression of VEGFR genes. The siNA are potentially
 CC useful for treating a wide range of angiogenesis-associated conditions,
 CC particularly cancers, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
 CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
 CC drug screening, target identification and validation, genetic
 CC engineering, studying gene function, and also for gene mapping (e.g. of
 CC single-nucleotide polymorphisms). The present sequence is used in the
 CC exemplification of the present invention.
 XX
 SQ Sequence 21 BP; 6 A; 5 C; 4 G; 2 T; 4 U; 0 Other;
 Query Match 90.5%; Score 19; DB 10; Length 21;
 Best Local Similarity 100.0%; Pred. No. 1.8;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 CUGAGUUUAAAAGGCACCC 19
 DB 1 CUGAGUUUAAAAGGCACCC 19
 RESULT 12
 ADF37895
 ID ADF37895 standard; RNA; 21 BP.
 XX
 AC ADF37895;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2092.
 XX
 KW double-stranded short interfering nucleic acid;
 KW short interfering nucleic acid; siNA; downregulation;
 KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
 KW cyostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
 KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
 KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
 KW arthritis; psoriasis; endometriosis; angiofibroma;
 KW polycystic kidney disease; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO2003070910-A2.
 XX
 PD 28-AUG-2003.
 XX
 PF 20-FEB-2003; 2003WO-US0005022.
 XX
 PR 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 29-MAY-2002; 2002WO-US017674.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 03-JUL-2002; 2002US-0393796P.
 PR 29-JUL-2002; 2002US-0399348P.
 PR 29-AUG-2002; 2002US-0406784P.

PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 04-NOV-2002; 2002US-00287949.
 PR 21-NOV-2002; 2002US-00306747.
 PR 15-JAN-2003; 2003US-0440129P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Mcswiggen J, Beigelman L, Pavco P;
 PI WPI; 2003-679876/64.
 XX
 DR New double-stranded interfering nucleic acid, useful e.g. for treatment
 XX and diagnosis of cancer, downregulates the vascular endothelial growth
 PT factor receptor gene.
 PT
 XX Example 3; SEQ ID NO 2092; 207pp; English.
 PS
 CC The present invention describes a double-stranded short interfering
 CC nucleic acid (siNA) that downregulates expression of the vascular
 CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
 CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
 CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
 CC that express siNA; and (5) single-stranded siNA with similar properties.
 CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
 CC ophthalmological, antiarthritic, antipsoriatic, nephrotropic and
 CC gynaecological activities. The siNA are useful for modulating
 CC (downregulating) the expression of VEGFR genes. The siNA are potentially
 CC useful for treating a wide range of angiogenesis-associated conditions,
 CC particularly cancers, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiofibroma,
 CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
 CC drug screening, target identification and validation, genetic
 CC engineering, studying gene function, and also for gene mapping (e.g. of
 CC single-nucleotide polymorphisms). The present sequence is used in the
 CC exemplification of the present invention.
 XX
 SQ Sequence 21 BP; 6 A; 5 C; 4 G; 2 T; 4 U; 0 Other;
 Query Match 90.5%; Score 19; DB 10; Length 21;
 Best Local Similarity 100.0%; Pred. No. 1.8;
 Matches 19; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 CUGAGUUUAAAAGGCACCC 19
 DB 1 CUGAGUUUAAAAGGCACCC 19
 RESULT 13
 ADF37739/C
 ID ADF37739 standard; RNA; 21 BP.
 XX
 AC ADF37739;
 XX
 DT 12-FEB-2004 (first entry)
 XX
 DE Human VEGFR1 short interfering nucleic acid (siNA) SEQ ID NO:2152.
 XX
 KW double-stranded short interfering nucleic acid;
 KW short interfering nucleic acid; siNA; downregulation;
 KW vascular endothelial growth factor receptor; VEGFR; antiangiogenic;
 KW cyostatic; antidiabetic; ophthalmological; antiarthritic; antipsoriatic;
 KW nephrotropic; gynaecological; angiogenesis-associated condition; cancer;
 KW diabetic retinopathy; macular degeneration; neovascular glaucoma;
 KW arthritis; psoriasis; endometriosis; angiofibroma;
 KW polycystic kidney disease; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO2003070910-A2.
 XX
 PD 28-AUG-2003.

```

XX PF 20-FEB-2003; 2003WO-US005022.
XX OS Unidentified.
XX OS Synthetic.
XX PN WO2003074654-A2.
XX XX
XX PD 12-SEP-2003.
XX XX
XX PF 20-FEB-2003; 2003WO-US005028.
XX XX
XX PR 20-FEB-2002; 2002US-0358580P.
XX PR 11-MAR-2002; 2002US-0363124P.
XX PR 06-JUN-2002; 2002US-0386782P.
XX PR 29-AUG-2002; 2002US-0406784P.
XX PR 05-SEP-2002; 2002US-0408378P.
XX PR 09-SEP-2002; 2002US-0409293P.
XX PR 15-JAN-2003; 2003US-0440129P.
XX PA (SIRN-) SIRNA THERAPEUTICS INC.
XX PI Mcswiggen J, Beigelman L, Pavco P;
XX PI Jamison S, Usman N, Thompson J;
XX PI WPI; 2003-731676/69.
XX DR
XX XX
XX PT New double-stranded short interfering nucleic acid molecule, useful for
XX PT down-regulating the expression of an endogenous mammalian target gene or
XX PT for treating diseases that respond to modulation of gene expression or
XX PT activity.
XX PS Example 24; SEQ ID NO 402; 593pp; English.
XX CC The invention relates to a double-stranded short interfering nucleic acid
XX CC (siNA) molecule that down-regulates expression of an endogenous mammalian
XX CC target gene comprising one or more chemical modifications and each strand
XX CC of the double-stranded siNA comprises about 21 nucleotides. The siNA of
XX CC the invention demonstrates antiarteriosclerotic, neuroprotective,
XX CC neurotropic, antiparkinsonian and anticonvulsant activities and may be
XX CC useful for down-regulating the expression of an endogenous mammalian
XX CC target gene and therefore in the treatment of any disease or condition
XX CC that responds to modulation of gene expression or activity in a cell,
XX CC tissue or organism. The disease or condition may include pulmonary
XX CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
XX CC Parkinson's disease, epilepsy, dementia, huntington's disease or
XX CC amyotrophic lateral sclerosis. Furthermore, the siNA may be utilised for
XX CC gene therapy applications. The current sequence is that of the siNA DNA-
XX CC RNA hybrid of the invention.
XX SQ Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

Query Match 90.5%; Score 19; DB 10; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.8;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 15
ADG29884/c
ID ADG29884 standard; RNA; 21 BP.
XX AC
XX AC ADG29884;
XX DT 26-FEB-2004 (first entry)
XX DE
XX DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 450.
XX KW double-stranded short interfering nucleic acid; siNA;
XX KW antiarteriosclerotic; neuroprotective; neurotropic; antiparkinsonian;
XX KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
XX KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
XX KW amyotrophic lateral sclerosis; gene therapy; es; DNA-RNA hybrid; FLT1.

XX PF 20-FEB-2003; 2003WO-US005022.
XX OS Unidentified.
XX OS Synthetic.
XX PN WO2003074654-A2.
XX XX
XX PD 12-SEP-2003.
XX XX
XX PF 20-FEB-2003; 2003WO-US005028.
XX XX
XX PR 20-FEB-2002; 2002US-0358580P.
XX PR 11-MAR-2002; 2002US-0363124P.
XX PR 06-JUN-2002; 2002US-0386782P.
XX PR 29-AUG-2002; 2002US-0406784P.
XX PR 05-SEP-2002; 2002US-0408378P.
XX PR 09-SEP-2002; 2002US-0409293P.
XX PR 15-JAN-2003; 2003US-0440129P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J, Beigelman L, Pavco P;
XX PI WPI; 2003-679876/64.
XX DR
XX XX
XX PT New double-stranded interfering nucleic acid, useful e.g. for treatment
XX PT and diagnosis of cancer, downregulates the vascular endothelial growth
XX PT factor receptor gene.
XX PS Example 3; SEQ ID NO 2152; 207pp; English.
XX CC The present invention describes a double-stranded short interfering
XX CC nucleic acid (siNA) that downregulates expression of the vascular
XX CC endothelial growth factor receptor (VEGFR) gene. Also described: (1) a
XX CC siNA that downregulates the VEGF gene; (2) kits for in vitro or in vivo
XX CC delivery of siNA; (3) conjugates and/or complexes of siNA; (4) vectors
XX CC that express siNA; and (5) single-stranded siNA with similar properties.
XX CC The siNAs have antiangiogenic, cytostatic, antidiabetic,
XX CC ophthalmological, antiarthritic, antipsoriatic, antineoplastic and
XX CC gynaecological activities. The siNA are useful for modulating
XX CC (downregulating) the expression of VEGFR genes. The siNA are potentially
XX CC useful for treating a wide range of angiogenesis-associated conditions,
XX CC particularly cancers, diabetic retinopathy, macular degeneration,
XX CC neovascular glaucoma, arthritis, psoriasis, endometriosis, angiodysplasia,
XX CC and polycystic kidney disease. The siNA may also be useful for diagnosis,
XX CC drug screening, target identification and validation, genetic
XX CC engineering, studying gene function, and also for gene mapping (e.g. of
XX CC single-nucleotide polymorphisms). The present sequence is used in the
XX CC exemplification of the present invention.
XX SQ Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;

Query Match 90.5%; Score 19; DB 10; Length 21;
Best Local Similarity 78.9%; Pred. No. 1.8;
Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAGGCACCC 19
Db 19 CTGAGTTTAAAGGCACCC 1

RESULT 14
ADG29836/c
ID ADG29836 standard; RNA; 21 BP.
XX AC
XX AC ADG29836;
XX DT 26-FEB-2004 (first entry)
XX DE
XX DE FLT1-targeted siNA DNA-RNA hybrid - SEQ ID 402.
XX KW double-stranded short interfering nucleic acid; siNA;
XX KW antiarteriosclerotic; neuroprotective; neurotropic; antiparkinsonian;
XX KW anticonvulsant; pulmonary disease; restenosis; atherosclerosis;
XX KW Alzheimer's; Parkinson's; epilepsy; dementia; huntington's;
XX KW amyotrophic lateral sclerosis; gene therapy; es; DNA-RNA hybrid; FLT1.

```

KW anyotropic lateral sclerosis; gene therapy; ss; DNA-RNA hybrid; FLTL.
 XX Unidentified.
 OS Synthetic.
 XX WO2003074654-A2.
 PN 12-SEP-2003.
 XX 20-FEB-2003; 2003WO-US005028.
 XX 20-FEB-2002; 2002US-0358580P.
 PR 11-MAR-2002; 2002US-0363124P.
 PR 06-JUN-2002; 2002US-0386782P.
 PR 29-AUG-2002; 2002US-0406784P.
 PR 05-SEP-2002; 2002US-0408378P.
 PR 09-SEP-2002; 2002US-0409293P.
 PR 15-JAN-2003; 2003US-0440129P.
 XX (SIRN-) SIRNA THERAPEUTICS INC.
 PA McSwiggen J, Beigelman L, Chowira B, Pavco P, Fosnaugh K;
 PI Jamison S, Usman N, Thompson J;
 DR WPI; 2003-731676/69.
 XX New double-stranded short interfering nucleic acid molecule, useful for
 PT down-regulating the expression of an endogenous mammalian target gene or
 PT for treating diseases that respond to modulation of gene expression or
 PT activity.
 XX Example 24; SEQ ID NO 450; 593pp; English.
 PS The invention relates to a double-stranded short interfering nucleic acid
 CC (siRNA) molecule that down-regulates expression of an endogenous mammalian
 CC target gene comprising one or more chemical modifications and each strand
 CC of the double-stranded siRNA comprises about 21 nucleotides. The siRNA of
 CC the invention demonstrates antiarteriosclerotic, neuroprotective,
 CC neurotropic, antiparkinsonian and anticonvulsant activities and may be
 CC useful for down-regulating the expression of an endogenous mammalian
 CC target gene and therefore in the treatment of any disease or condition
 CC that responds to modulation of gene expression or activity in a cell,
 CC tissue or organism. The disease or condition may include pulmonary
 CC diseases such as restenosis, atherosclerosis, Alzheimer's disease,
 CC Parkinson's disease, epilepsy, dementia, Huntington's disease or
 CC anyotropic lateral sclerosis. Furthermore, the siRNA may be utilised for
 CC gene therapy applications. The current sequence is that of the siRNA DNA-
 CC RNA hybrid of the invention.
 XX SQ Sequence 21 BP; 4 A; 4 C; 5 G; 2 T; 6 U; 0 Other;
 Query Match 90.5%; Score 19; DB 10; Length 21;
 Best Local Similarity 78.9%; Pred.No. 1.8;
 Matches 15; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

QY 1 CUGAGUUUAAAAGGCACCC 19
 Db 19 CTGAGTTTAAAGGCACCC 1

Search completed: August 19, 2005, 00:19:44
 Job time : 418 secs

Result No.	Score	Query Match	Length	DB	ID	Description
1	17	81.0	17	6	AR186006	AR186006 Sequence
2	17	81.0	17	6	AR191755	AR191755 Sequence
3	17	81.0	17	6	AR322637	AR322637 Sequence
C	4	17	81.0	20	AR489901	AR489901 Sequence
	5	16	76.2	17	AR186005	AR186005 Sequence
	6	16	76.2	17	AR191754	AR191754 Sequence
	7	16	76.2	17	AR322636	AR322636 Sequence
C	8	15	76.2	20	AR489902	AR489902 Sequence
	9	15	71.4	17	AR186004	AR186004 Sequence
	10	15	71.4	17	AR191753	AR191753 Sequence
	11	15	71.4	17	AR322635	AR322635 Sequence
C	12	14.2	67.6	22	BD233486	BD233486 Novel hum
	13	14.2	67.6	24	BD233487	BD233487 Novel hum
C	14	13.8	65.7	21	SSA37790	AJ000790 Sus scrofa
	15	13.8	65.7	28	A98496	A98496 Sequence 6
16	13.2	62.9	30	6	AR063801	AR063801 Sequence
17	13.2	62.9	30	6	I30164	I30164 Sequence 86
C	18	12.8	61.0	19	AR298136	AR298136 Sequence
	19	12.8	61.0	21	CQ831028	CQ831028 Sequence

TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7243 12-FEB-2002;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN

Query Match 81.0%; Score 17; DB 6; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.8e+03;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCAC 17
|:||||:|||||||
Db 1 CTGAGTTTAAAGGCAC 17

RESULT 3
LOCUS AR322637 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 39 from patent US 6566127.
ACCESSION AR322637
VERSION AR322637.1 GI:33708445
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 39 20-MAY-2003;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"

ORIGIN

Query Match 81.0%; Score 17; DB 6; Length 17;
Best Local Similarity 76.5%; Pred. No. 1.8e+03;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCAC 17
|:||||:|||||||
Db 1 CTGAGTTTAAAGGCAC 17

RESULT 4
LOCUS AR489901/c 20 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 24 from patent US 6710174.
ACCESSION AR489901
VERSION AR489901.1 GI:47257014
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Watt,A.T.
TITLE Antisense inhibition of vascular endothelial growth factor receptor-1 expression
JOURNAL Patent: US 6710174-A 24 23-MAR-2004;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"

ORIGIN

Query Match 81.0%; Score 17; DB 6; Length 20;
Best Local Similarity 76.5%; Pred. No. 1.7e+03;
Matches 13; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCAC 17
|:||||:|||||||
Db 17 CTGAGTTTAAAGGCAC 1

RESULT 5
LOCUS AR186005 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 1493 from patent US 6346398.
ACCESSION AR186005
VERSION AR186005.1 GI:20231970
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 1493 12-FEB-2002;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN

Query Match 76.2%; Score 16; DB 6; Length 17;
Best Local Similarity 75.0%; Pred. No. 5.8e+03;
Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCAC 16
|:||||:|||||||
Db 2 CTGAGTTTAAAGGCAC 17

RESULT 6
LOCUS AR191754 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7242 from patent US 6346398.
ACCESSION AR191754
VERSION AR191754.1 GI:20237719
KEYWORDS
SOURCE Unknown.
ORGANISM Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7242 12-FEB-2002;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"

ORIGIN

Query Match 76.2%; Score 16; DB 6; Length 17;
Best Local Similarity 75.0%; Pred. No. 5.8e+03;
Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CUGAGUUUAAAAGGCAC 16
|:||||:|||||||
Db 2 CTGAGTTTAAAGGCAC 17

RESULT 7
LOCUS AR322636 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 38 from patent US 6566127.
ACCESSION AR322636
VERSION AR322636.1 GI:33708444
KEYWORDS
SOURCE Unknown.

ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 38 20-MAY-2003;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"
ORIGIN
Query Match 76.2%; Score 16; DB 6; Length 17;
Best Local Similarity 75.0%; Pred. No. 5.8e+03;
Matches 12; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CUGAGUUUAAAAGGCA 16
Db 2 CTGAGTTTAAAAGGCA 17
RESULT 8
LOCUS AR489902/c 20 bp DNA linear PAT 15-MAY-2004
DEFINITION Sequence 25 from patent US 6710174.
ACCESSION AR489902
VERSION AR489902.1 GI:47257015
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 20)
AUTHORS Bennett,C.F. and Watt,A.T.
TITLE Antisense inhibition of vascular endothelial growth factor receptor-1 expression
JOURNAL Patent: US 6710174-A 25 23-MAR-2004;
FEATURES Location/Qualifiers
source
1. .20
/organism="unknown"
/mol_type="genomic DNA"
ORIGIN
Query Match 76.2%; Score 16; DB 6; Length 20;
Best Local Similarity 81.2%; Pred. No. 5.6e+03;
Matches 13; Conservative 3; Mismatches 0; Indels 0; Gaps 0;
Qy 4 AGUUUAAAAGGCACCC 19
Db 20 AGTTTAAAAGGCACCC 5
RESULT 9
LOCUS AR186004 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 1492 from patent US 6346398.
ACCESSION AR186004
VERSION AR186004.1 GI:20231969
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 1492 12-FEB-2002;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"
ORIGIN

Query Match 71.4%; Score 15; DB 6; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.9e+04;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CUGAGUUUAAAAGGC 15
Db 3 CTGAGTTTAAAAGGC 17
RESULT 10
LOCUS AR191753 17 bp DNA linear PAT 20-APR-2002
DEFINITION Sequence 7241 from patent US 6346398.
ACCESSION AR191753
VERSION AR191753.1 GI:20237718
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J., Stinchcomb,D. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6346398-A 7241 12-FEB-2002;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned DNA"
ORIGIN
Query Match 71.4%; Score 15; DB 6; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.9e+04;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CUGAGUUUAAAAGGC 15
Db 3 CTGAGTTTAAAAGGC 17
RESULT 11
LOCUS AR322635 17 bp RNA linear PAT 17-AUG-2003
DEFINITION Sequence 37 from patent US 6566127.
ACCESSION AR322635
VERSION AR322635.1 GI:33708443
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
Unclassified.
REFERENCE 1 (bases 1 to 17)
AUTHORS Pavco,P., McSwiggen,J.A., Stinchcomb,D.T. and Escobedo,J.
TITLE Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
JOURNAL Patent: US 6566127-A 37 20-MAY-2003;
FEATURES Location/Qualifiers
source
1. .17
/organism="unknown"
/mol_type="unassigned RNA"
ORIGIN
Query Match 71.4%; Score 15; DB 6; Length 17;
Best Local Similarity 73.3%; Pred. No. 1.9e+04;
Matches 11; Conservative 4; Mismatches 0; Indels 0; Gaps 0;
Qy 1 CUGAGUUUAAAAGGC 15
Db 3 CTGAGTTTAAAAGGC 17
RESULT 12
LOCUS BD233486/c 22 bp DNA linear PAT 17-JUL-2003
DEFINITION Novel human thrombopoietin derivative having elevated capability of

PC	C12P21/02.C12N15/00.A61K37/24.C12N5/00
CC	Synthetic oligodeoxynucleotide primer 30-C
FH	Key Location/Qualifiers
FT	source 1..24
FT	Location/Qualifiers 1..24 /organism='Artificial Sequence'.
 FEATURES source	
1..24 /organism="synthetic construct" /mol_type="genomic DNA" /db_xref="taxon:32630"	
 ORIGIN	
Query Match	67.6%; Score 14.2; DB 6; Length 24;
Best Local Similarity	68.4%; Pred. No. 4.6e+04;
Matches 13; Conservative	3; Mismatches 3; Indels 0; Gaps 0;
QY	1 CUGAGUUUAAAGGCACC 19
DB	: 4 CAGAGTTTAAACGGAACCC 22
 RESULT 14	
SSAJ790/c	21 bp mRNA linear MAM 29-JUL-1997
LOCUS	Sus scrofa EST 3'UTR KICT reverse primer.
DEFINITION	AJ000790
ACCESSION	AJ000790.1 GI:2286013
VERSION	PCR primer.
KEYWORDS	Sus scrofa (pig)
SOURCE	Sus scrofa
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus. 1 (bases 1 to 21) Fridolfsson,A.K., Hori,T., Wintero,A.K., Fredholm,M., Verle,M., Robic,A., Andersson,L. and Ellegren,H. Expansion of the pig comparative map by expressed sequence tags (EST) mapping Unpublished 2 (bases 1 to 21) Fridolfsson,A.K. Direct Submission Submitted (27-JUL-1997) Fridolfsson A.K., Animal Breeding and Genetics, Swedish University of Agricultural Sciences, Biomedical Center, Box 597, S-751 24 Uppsala, SWEDEN Location/Qualifiers 1..21 /organism="Sus scrofa" /mol_type="mRNA" /db_xref="taxon:9823" /chromosome="12" /map="12p"
 FEATURES source	
1..21 /organism="Sus scrofa" /mol_type="mRNA" /db_xref="taxon:9823" /chromosome="12" /map="12p"	
 ORIGIN	
Query Match	65.7%; Score 13.8; DB 4; Length 21;
Best Local Similarity	64.7%; Pred. No. 7.7e+04;
Matches 11; Conservative	4; Mismatches 2; Indels 0; Gaps 0;
QY	2 UGAGUUUAAAGGCACC 18
DB	: : 21 TGAGTTTAAAGGCAGC 5
 RESULT 15	
A98496/c	28 bp DNA linear PAT 26-JAN-2000
LOCUS	A98496
DEFINITION	Sequence 6 from Patent WO9911784.
ACCESSION	A98496
VERSION	A98496.1 GI:6781596
KEYWORDS	Rattus sp.
SOURCE	Rattus sp.
ORGANISM	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;

```

REFERENCE 1 (bases 1 to 28)
AUTHORS   England,S. and Chen,C.
TITLE     PROTON GATED ION CHANNEL PROTEINS
JOURNAL   Patent: WO 9911784-A 6 11-MAR-1999;
          ENGLAND STEVE (GB); UNIV LONDON (GB)
FEATURES
  source   1..28
            /organism="Rattus sp."
            /mol_type="unassigned DNA"
            /db_xref="taxon:10118"
            /tissue_type="DORSAL ROOT GANGLION"

ORIGIN

Query Match      65.7%; Score 13.8; DB 6; Length 28;
Best Local Similarity 76.5%; Pred. No. 7.2e+04;
Matches 13; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY  3  GAGUUUAAAGGCACCC 19
    |||::|||||
Db  18 GAGGTTAAAGGCTCCC 2

Search completed: August 19, 2005, 00:47:36
Job time : 1662 secs

```

This Page Blank (uspto)